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AB S TR A C T  
 
 
Plasmalogens are a class of ether-phospholipids with fundamental structural 
and functional roles in biological membranes. They are distributed throughout 
different tissues albeit in varied proportions, being the nervous tissue particularly 
rich in these phospholipids. The biosynthetic pathway of plasmalogens occurs in a 
bi-localized manner. The first two steps occur in the peroxisome and the remaining 
in the endoplasmic reticulum. Therefore, syndromes which have the assembly of 
peroxisomes compromised generate an impairment in plasmalogen biosynthesis 
which leads to a deficiency in plasmalogens. Rhizomelic chondrodysplasia punctata 
(RCDP), a peroxisomal disorder caused by deficiency in the biosynthesis of 
plasmalogens, highlights the importance of plasmalogens in multiple tissues, as the 
patients present cataracts, abnormal endochondral ossification, hypotonia and 
mental retardation. As reduced plasmalogen levels have been observed in 
neurodegenerative disorders (e.g. X-linked adrenoleukodystrophy and Alzheimer’s 
disease) it is of special importance to understand the consequences and functions of 
these phospholipids in nervous tissue. 
Using two mouse models with a complete impairment in the plasmalogens 
biosynthesis pathway (Pex7 and Gnpat knockout mice (KO)) we determined the 
importance of plasmalogens in myelination and the consequences of a plasmalogen 
deficiency in the peripheral nervous system. 
Results obtained showed that the absence of plasmalogens affects 
myelination and radial sorting. As hypomyelination was a feature in the nerves of 
young KO mice, we also characterized myelin and Schwann cell morphology in adult 
mice. Our results show that in the absence of plasmalogens and despite normal 
amounts, myelin is abnormally formed with an increase in non-compact myelin 
(higher number of Schmidt Lanterman incisures) and incorrect compartmentalization 
of the Schwann cell cytoplasm. In aged KO mice, the lack of plasmalogens causes a 
severe demyelination and axonal loss. Evaluations of the molecular mechanisms 
behind the defect in myelination demonstrated a defect in the AKT-mediated 
signalling pathway due to an impairment in AKT recruitment to the plasma 
membrane. By unravelling the pathology and the mechanism of disease, we were 
able to devise and determine the effectiveness of a therapeutic strategy aimed at 
inhibiting GSK3, a downstream effector of the AKT-mediated signalling pathway. 
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Using lithium, a well known GSK3 inhibitor, we showed that there was a rescue of 
the defective radial sorting and myelination. 
 Combined, our results unravelled a new role of plasmalogens in cellular 
biology, characterized the pathology caused by a deficiency in plasmalogens and 
determined the mechanisms behind it. Future work should include the 
determination if a lithium treatment may have beneficial effects in adult knockout 
mice or if combined therapies have a truly therapeutic potential. 
 
 
Keywords: AKT; ether-phospholipids; Gnpat; myelination; mouse knockout; 
plasmalogens; PNS; radial sorting; rhizomelic chondrodysplasia punctata; Schwann 
cell; therapy  
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R E S U M O  
 
 
 Os plasmalogénios são uma classe de éter fosfolípidos com funções 
estruturais e funcionais fundamentais nas membranas biológicas. Estes encontram-
se distribuídos em vários tecidos embora que em variadas proporções, sendo o 
tecido nervoso particularmente rico nestes fosfolípidos. Na via biossintética dos 
plasmalogénios, os primeiros dois passos dão-se no peroxissoma e os restantes no 
retículo endoplasmático. Deste modo, síndromes onde a formação dos 
peroxissomas esteja comprometida levam a um défice de plasmalogénios por um 
bloqueio na sua biossíntese. A Condrodisplasia Rizomélica punctata (CDRP), uma 
doença peroxissomal causada por uma deficiência na biossíntese de 
plasmalogénios, realça a importância dos plasmalogénios em variados tecidos, uma 
vez que os pacientes apresentam cataratas, defeitos na ossificação endocondral, 
hipotonia e atraso mental. Uma vez que níveis reduzidos de plasmalogénios têm 
sido observados em doenças neurodegenerativas (ex. Adrenoleucodistrofia ligada ao 
cromossoma X e doença de Alzheimer), é de especial importância entender as 
consequências e as funções destes fosfolípidos no tecido nervoso. 
 Utilizando dois modelos de ratinho com um dano completo na via 
biossintética de plasmalogénios (ratinhos Pex7 e Gnpat knockout (KO)), 
investigámos a importância dos plasmalogénios na mielinização e as consequências 
da deficiência destes no sistema nervoso periférico. 
 Os resultados obtidos demonstraram que a ausência de plasmalogénios 
afecta a mielinização e o radial sorting. Dado que nós observámos uma 
hipomielinização em nervos ciáticos de ratinhos KO jovens também se caracterizou 
a morfologia da mielina e da célula de Schwann em ratinhos adultos. Os resultados 
demonstraram que na ausência de plasmalogénios e apesar dos valores normais de 
mielina, esta foi formada anormalmente pois possuía um aumento em mielina não 
compacta (aumento no número de incisuras de Schmidt Lanterman) e uma 
compartimentalização incorrecta do citoplasma da célula de Schwann. Em ratinhos 
KO envelhecidos, a ausência de plasmalogénios mostrou provocar uma 
demielinização pronunciada e perda axonal. A determinação dos mecanismos 
moleculares associados ao defeito na mielinização observado demonstraram um 
defeito na activação da via de sinalização mediada por AKT devido a um 
recrutamento defeituoso da AKT para a membrana plasmática. Desvendando a 
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patologia e o mecanismo da doença, foi-nos permitido desenhar e determinar a 
eficácia de uma estratégia terapêutica consistindo na inibição da GSK3β, um efector 
que se encontra na base da via de sinalização mediada pela AKT. Utilizando Lítio, 
um conhecido inibidor da GSK3β, demonstrou-se que existe uma recuperação na 
deficiência na mielinização e no radial sorting. 
 Combinados, os nossos resultados desvendaram um novo papel dos 
plasmalogénios na biologia celular, permitiram a caracterização da patologia 
causada por uma deficiência em plasmalogénios e a determinação dos mecanismos 
por trás desta deficiência. Trabalho futuro deveria determinar se o tratamento com 
Lítio poderá ter efeitos benéficos em ratinhos KO adultos ou se terapias combinadas 
poderão ter verdadeiramente um potencial terapêutico. 
 
 
Palavras chave: AKT; Célula de Schwann; condrodisplasia rizomélica punctata; éter-
fosfolípidos; Gnpat; mielinização; plasmalogénios; radial sorting; ratinho knockout; 
SNP; terapia 
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GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
Gnpat    Glycerone-phosphate O-acyltransferase 
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GPC    Glycero-3-phosphocholine 
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GSK3β   Glycogen synthase kinase 3 β 
GTA    Glutaraldehyde 
ICC    Immunocytochemistry 
Jnk    c-Jun N-terminal kinase 
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+
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NaCl    Sodium chloride 
NDS    Normal Donkey Serum 
NFATc4   Nuclear factor of activated T-cells 
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NGF    Nerve growth factor 
NPC    Niemann Pick Type C Disease 
NRG1-III   Neuregulin-1 type III 
O/N    Over-night 
Oct6    Octamer-binding transcription factor-6 
OD    Optical density 
P(x)    Post natal day (x) 
P/S    Penicillin/Streptomycin 
P0    Myelin protein zero 
PAF    Platelet activating factor 
PBD    Peroxisomal biogenesis disorder 
PBS    Phosphate buffered saline pH 7.6 
PC-plasmalogen  Plasmenylcholine plasmalogen 
PE-plasmalogen  Plasmenylethanolamine plasmalogen 
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PH    Phosphohydrolase 
PhyH    Phytanoyl-CoA hydroxylase  
PI3K    Phosphatidylinositol 3-kinase 
PIP3    Phosphatidylinositol (3,4,5)-triphosphate 
PLC-γ    Phospholipase C-γ 
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PPD    p-phenylenediamine 
PsPLA2   Plasmalogen specific phospholipase A2 
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PTS1    Peroxisomal targeting signal 1 
PTS2    Peroxisomal targeting signal 2 
PUFA    Polyunsaturated fatty acid 
RCDP    Rhizomelic Chondrodysplasia punctata 
ROS    Reactive Oxygen Species 
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RTK    Receptor tyrosine kinase 
SC    Schwann cell 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
Ser    Serine 
SLI    Schmidt Lanterman Incisures 
SNP    Sistema nervoso Periférico 
Sox10    SRY-related HMG-box10 
Sox2    SRY-related box2 
Stat3    Signal transducer and activator of transcription 3 
TBS    Tris-buffered saline 
Thr    Threonine 
Tyr    Tyrosine 
VLCFA    Very long chain fatty acid 
WB    Western Blot 
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Yy1    Yin yang-1 
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PHOSPHOLIPIDS 
 
Lipids are a class of organic molecules with well described and very 
important biological functions. The nervous system is reliant on the roles of 
specific phospholipids which may act as structural components of myelin and 
may also incorporate the mediation of signalling processes. 
Glycerophospholipids constitute a subclass of phospholipids and represent 
the majority of the lipid content in biological membranes. Structurally, they 
contain fatty acid ester linkages at sn1 and sn2 positions (Figure 1A) [1].  
A special class of glycerophospholipids are the ether linked 
glycerophospholipids that contain an ether linked to the sn1 position rather than 
an ester (Figure 1 B). In a general way, ether glycerophospholipids consist of a 
glycerol backbone which contains attached at the sn-1 and sn-2 positions long 
fatty acid chains and attached to the sn-3 position is a varying polar head group 
[2]. 
At the sn-1 position there are two types of ether bonds that may occur in 
these ether-phospholipids: the ether bond, mentioned previously, which is 
present in platelet activating factor (PAF) and the vinyl-ether bond occurring in 
plasmalogens (Figure 1 C) [3].  
 
   
 
 
Figure 1. Overview of the structure of Glycerophospholipids. Represented in the image is the 
structure of a glycerophospholipid (A), an ether-glycerophospholipid (B) and a vinyl-ether 
glycerophospholipid (C) also known as Plasmalogen. Plasmalogens may have one of two different head 
groups: choline or ethanolamine (D). Highlighted is the glycerol backbone. Adapted from [3], [4]. 
sn1 
sn2 
sn3 
A B 
C D 
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PLASMALOGENS  
 
Plasmalogens (1-O-alk-1’-enyl-2-acyl glycerophospholipids) belong, as 
described above, to a subclass of ether phospholipids and are characterized by 
the presence of a cis double bond on the alkyl chain adjacent to the ether linkage 
at the sn-1 position giving rise to the characteristic vinyl-ether bond [2], [3], [5]. 
These vinyl-ether phospholipids were first described in 1924 by Feulgen 
and Voit [6] when they discovered during a routine nuclear staining technique a 
lipidic compound which was insoluble in water but easily extracted with organic 
solvents. They verified that in the presence of acid or mercuric chloride, the then 
unknown substance suffered a reaction which led to the formation of an aldehyde 
as it was stained with fuchsinsulfurous acid. This substance known to be an 
aldehyde was named “plasmal” since it was present in the plasma and the 
termination was due to its aldehyde nature. The precursor was named 
“plasmalogen” owed to its capacity to generate “plasmal” [6]. 
 Plasmalogens have a very well characterized and defined structure in which 
the sn-1 position is usually occupied by a 16:0 (palmitic acid), 18:0 (stearic acid) 
or 18:1 (oleic acid) carbon chain, the sn-2 position is occupied by a 
polyunsaturated fatty acid (PUFA) and the sn-3 is occupied by one of the two polar 
head groups: ethanolamine or choline which give rise to plasmenylethanolamine 
and plasmenylcholine plasmalogens respectively [3]. These two types of 
plasmalogens exist in human tissues in different proportions where PE-
plasmalogen is in general more abundant than PC-plasmalogen with exception of 
the heart muscle where PC-plasmalogen dominates in abundance [7]. 
The distribution of plasmalogens among living organisms is extensive and 
they are present in anaerobic bacteria, some fungi, higher plants, invertebrates 
and vertebrates, including mammals and man [8], [9]. They play important roles 
in the function and structure maintenance of biological membranes [3], [5], [10], 
[11], as well as in the storage of long chain polyunsaturated fatty acids (PUFAs), 
ion transport [12], [13] and lipid secondary messenger genesis [10].  
Regarding mammalian tissues, they are widely abundant and consist of 
approximately 18% of the total phospholipid content in humans. The relative 
amount and composition of plasmalogens varies among the different tissues, 
being these ether-phospholipids more abundant in the brain, heart, inflammatory 
cells and spermatozoa (table 1) [2].  Plasmalogens’ distribution varies depending 
Chapter I │ Introduction 
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on the species [9]. Furthermore, regarding its topology, plasmalogens have an 
asymmetric distribution in biological membranes [14]. PE-plasmalogens are 
mostly found in the inner leaflet of the plasma membrane such as in the case of 
sarcolemmal membrane, in red blood cells and myelin [14], [15], [16]. 
  
Table 1. Representation of plasmalogen distribution in human cells and tissues. Human brain, heart, 
inflammatory cells and spermatozoa are particularly rich in these ether-phospholipids. Adapted from 
[10] and [2]. 
Tissues
/Cells 
Human 
Heart 
Human 
Brain 
Inflammatory 
cells 
Human 
Plasma 
Human 
Spermatozoa 
Human 
Kidney 
Human 
Lungs 
8-20 % 32-50 % 20-50 % Up to 50 % 5 % 55 % 20-40 % 20-40 % 
 
 
 
PLASMALOGENS’ BIOSYNTHETIC PATHWAY 
 
 The plasmalogens’ biosynthetic pathway starts with the action of the 
enzyme dihydroxyacetone phosphate acyltransferase (DHAP-AT) also known as 
glycerone-phosphate O-acyltransferase (Gnpat) where the esterification of 
dihydroxyacetone phosphate (DHAP) with an acyl-CoA ester leads to the 
formation of 1-acyl-DHAP (Figure 2). The second step of the biosynthetic pathway 
involves the introduction of the ether bond at the sn-1 position. At this point, 
alkyl-dihydroxyacetone phosphate synthase (ADHAP-S) also known as 
alkylglycerone phosphate synthase (Agps) replaces the fatty acid at the sn-1 
position by a fatty alcohol yielding 1-alkyl-DHAP [3]. 
 There are different possibilities for the origin of these fatty alcohols. On 
one hand they may be derived from dietary sources in the form of wax esters 
found in fish and vegetables [17], [18]. Other possibility is the reduction of fatty 
acids such as acyl-CoA chains catalysed by fatty acyl-CoA reductase [19], [20]. 
One third explanation for the origin of the fatty alcohol focuses on the 
peroxisomal β-oxidation with chain elongation of dodecanoyl-CoA inside this 
organelle [21]. 
 The third enzyme involved in the pathway is acyl/alkyl-dihydroxyacetone 
phosphate reductase (AADHAP-R) which has the function of reducing the ketone 
group at the sn-2 position in the glycerol backbone. The product of this reaction 
Chapter I │ Introduction 
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is 1-alkyl-sn-glycero-3-phosphate which is subsequently acylated to 1-alkyl-2-acyl-
sn-glycero-3-phosphate by alkyl/acyl-glycero-3-phosphate acyltransferase (AAG3P-
AT). The next step consists in the removal of the phosphate group by a 
phosphohydrolase (PH) originating 1-alkyl-2-acyl-sn-glycerol. The cytidine-
diphosphate-ethanolamine (CDP-ethanolamine) group is integrated through the 
action of ethanolamine phosphotransferase leading to the formation of 1-alkyl-2-
acyl-sn-glycero-3-phosphoethanolamine (1-alkyl-2-acyl-GPE). The last step in the 
formation of PE-plasmalogen consists in a desaturation reaction performed by a 
∆1-alkyl desaturase and a cytochrome b5-dependent microsomal electron 
transport system. Finally, the PC-plasmalogen formation occurs from PE-
plasmalogen through head group transformations, namely via a hydrolytic 
exchange mechanism [22]. 
 
 
 
 
 
The plasmalogens’ biosynthetic pathway is divided into two subcellular 
compartments. The first two reactions take place in the peroxisome since the 
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Figure 2. Representative illustration of the plasmalogens’ biosynthetic pathway. The first two steps 
occur exclusively in the peroxisome, the third step presents a bimodal localization being able to occur 
either on the external surface of the peroxisomal membrane or in the ER (Endoplasmic reticulum). The 
remaining biosynthetic pathway occurs in the ER. Adapted from [4]. 
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enzymes DHAP-AT and ADHAP-S have exclusive peroxisomal localization. The 
third step in this biosynthetic pathway has a bi-localized character as AADHAP-R 
has been described as having bimodal localization, being present in the 
peroxisomal membrane facing the cytosol and in the Endoplasmic Reticulum (ER). 
The remaining pathway occurs in the ER [2], [23]. 
 
 
 
PLASMALOGENS’ BIOLOGICAL AND PHYSIOLOGICAL FUNCTIONS 
 
Plasmalogens are important constituents of plasma membrane presenting 
themselves in varying but significant amounts depending on the tissue. 
Deficiency in these ether-phospholipids leads to an impairment in the 
membrane’s structure and functions. These impairments were demonstrated by 
experiments on plasmalogen deficient cells (usually skin fibroblasts) which 
reported decreased membrane intra- and extra-cellular cholesterol transport, 
impaired membrane traffic and impaired vesicular function [4]. 
Plasmalogens are included in the lipid mediation process as they serve as 
providers of arachidonic acid and docohexanoic acid and consequently as a 
reservoir of lipid secondary messengers. Plasmalogens are metabolized by a 
plasmalogen specific phospholipase A
2
 (psPLA2) which leads to the formation of 
lysoplasmalogens and the release of an aldehyde from the sn-1 position. 
Arachidonic and docohexanoic acid are released from the sn-2 position of 
plasmalogens through the action of a phospholipase, entering the eicosanoid 
formation pathway and the generation of the first wave of secondary messengers. 
Moreover, lysoplasmalogens exhibit the ability to increase membrane 
permeability allowing Ca
2+
 influx and generating a succeeding wave of secondary 
messenger response [24], [25]. These functions are intricately associated with an 
additional plasmalogen’s function where it acts as an important PUFA storage 
agent [3], [26], [12] that leads to the eicosanoids production such as 
prostaglandins and leukotrienes [4]. 
Regarding the involvement of plasmalogens in membrane dynamics, it is 
important to refer their involvement with lipid raft microdomains (LRMs). LRMs 
are specialized regions of the cell membrane particularly rich in cholesterol, 
glycosphingolipids and specific proteins involved in signal transduction, thence 
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being associated as important membrane regions of cellular signalling [27]. Due 
to their signalling functions, these LRMs are distinct from the rest of the cellular 
membrane concerning membrane fluidity and according to Pike et al. [28] 
ethanolamine plasmalogens are particularly abundant in these regions. This 
finding suggests a role for plasmalogens in the modulation of the membrane 
fluidity in lipid rafts [4], [27], [11].  
 Plasmalogens are also described as scavengers of reactive oxygen species 
and as antioxidant agents [29]. The presence of the acid-labile vinyl-ether bond 
which characterizes plasmalogens contributes to their susceptibility to oxidative 
attack in contrast to diacylphospholipids [30]. So, plasmalogens are able to use 
their ether-bond as bait acting as scavengers and protecting other phospholipids 
from oxidative damage [3]. Experiments using plasmalogen deficient cells from 
patients with peroxisomal biogenesis disorders (PBDs) showed an increase in the 
sensitivity to UV radiation exposure [31]. In addition, in normal cells, upon 
exposure to high oxidative conditions, the plasmalogen levels decrease, 
corroborating the possible function as scavengers [32]. 
 Taking all this, plasmalogens are associated to several biological functions 
which will have impact in different cellular processes (Figure 3). 
 
 
Figure 3. Functions proposed for plasmalogens versus the processes affected with their absence 
from the membranes. Plasmalogens are described to have several biological functions such as 
antioxidant activity, mediation of membrane dynamics and membrane signalling, among others. 
Furthermore, many biological functions are impaired with their absence such as bone and eye  
development, myelination and others. Plasmalogens are represented in this membrane as the beige 
phospholipid while the diacylphospholipid are represented in brown. Figure adapted from [3]. 
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PLASMALOGENS IN D ISEASE 
 
 In the past decades, plasmalogens have been reported to be involved in 
the pathology of several human disorders. The fact that plasmalogen levels are 
altered in several human disorders, leads to the deliberation that these ether 
phospholipids may play an important role in these diseases. 
 As previously referred, plasmalogens have a variety of biological functions 
that, when impaired, give rise to deficiencies in a number of physiological 
processes. There are some descriptions about plasmalogens’ roles in 
spermatogenesis and eye development. Spermatozoa are rich in ether 
phospholipids namely PC and PE plasmalogens. An important role of 
plasmalogens in the spermatogenic process was demonstrated both with Pex7 
[33] and Gnpat [5], [34] knockout mouse models in which testis from these 
mouse models demonstrated an arrested spermatogenic process, disorganized 
seminiferous tubules and infertility. Plasmalogens are also intricately involved in 
lens development demonstrated also with Gnpat [5] knockout mouse models. 
Plasmalogen deficiency leads to impaired anterior lens epithelial cell polarity and 
bilateral cataract [34]. Besides the ones referred above, there are several other 
roles associated to plasmalogens namely in the ossification [35] and myelination 
process [36]. 
 In a general way, plasmalogen deficiency associated human disorders are 
linked with an impaired peroxisomal biogenesis or function [2]. In fact, PBDs lack 
plasmalogens since the two first steps of the biosynthetic pathway occur 
exclusively in the peroxisome (Figure 2). 
 According to Nagan and Zoeller [2], disorders that lead to plasmalogen 
deficiency because of the absence of peroxisomes or lack of their function can be 
divided into three groups: 
 Group A disorders that are characterized by a generalized loss of 
peroxisomes (eg. Zellweger syndrome and Neonatal X-linked 
adrenoleukodystrophy); 
 Group B disorders that present the inability to target peroxisomal 
proteins to the peroxisome (eg. Rhizomelic chondrodysplasia punctata 
type 1); 
 Group C disorders that display a defect on a single peroxisomal enzyme 
or function (eg. Rhizomelic chondrodysplasia punctata type 2 and 3); 
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ZELLWEGER SYNDROME (ZS) 
ZS is considered the prototype of the group of peroxisomal diseases [37] 
and is defined as an autosomal recessive neonatal neurodegenerative disorder in 
which the peroxisome biogenesis is compromised leading to a generalized lack of 
peroxisomes [4]. Clinically, Zellweger syndrome patients exhibit craniofacial 
dysmorphism, hypotonia, growth retardation and neurological abnormalities [3]. 
Biochemically, there is an accumulation of very long chain fatty acids (VLCFA), bile 
acid intermediates, phytanic acid and pristanic acid, as well as reduced 
plasmalogen content [3], [37]. Regarding brain pathology, ZS patients display 
dysmyelination rather than demyelination and neuronal migration defects [37], 
which leads to the suggestion that the reduced levels of plasmalogens in the 
brain tissue in this syndrome may have a consequence in the neuronal migration 
and myelination abnormalities [38]. Observations that membrane fluidity is higher 
in Zellweger syndrome patients cells strengthens the idea that plasmalogens may 
be involved in membrane dynamics and also signal transduction [11]. 
 
 
RHIZOMELIC CHONDRODYSPLASIA PUNCTATA (RCDP) 
RCDP is an autosomal recessive peroxisomal disorder characterized by 
distinct pathological and biochemical features and a very short life expectancy 
[39]. 
Biochemically, it is characterized by an impairment in plasmalogens and 
other ether phospholipids synthesis [40], [41] mostly because the activity and 
expression levels of the two enzymes responsible for the de novo synthesis of 
plasmalogens – Gnpat and Agps – are severely compromised. RCDP patients 
exhibit rhizomelic limb shortening, short stature, cataracts, mental retardation, 
epiphyseal and extra-epiphyseal punctate calcifications [42], degeneration of 
chondrocytes from resting cartilage [41] and defects on endochondral ossification 
[35]. As referred previously, plasmalogens are a major component of myelin and 
consequently abundant in the nervous tissue. Thus, it is expectable that 
peroxisomal disorders such as RCDP in which the plasmalogen biosynthesis is 
impaired or even blocked, develop myelin deficiencies. This was confirmed in 
experiments using cells from RCDP patients [43] where through magnetic 
resonance imaging (MRI) it was observed that these patients demonstrated 
abnormal white matter signal representative of dysmyelination, designating to 
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RCDP pathological abnormalities in the myelination process in form of 
demyelination, dysmyelination or reduction of myelin volume [44].  
RCDP is a genetically heterogeneous disorder and is classified in three 
types that, although clinically indistinguishable, are divided according to defects 
in different genes [45]. 
RCDP type 1 is the most common of the three disorders [46]. It is 
characterized by mutations in the PEX7 gene. The corresponding protein, Peroxin 
7 (Pex7) belongs to the group of peroxisomal proteins and consists in a cytosolic 
receptor protein that recognizes proteins with the peroxisomal targeting signal 2 
(PTS2) and targets them to the peroxisome. With Pex7 inactivated, proteins 
carrying PTS2 fail in being imported to the peroxisome [46], [47] and remain in 
the cytosol. There are three proteins described as having PTS2. 3-oxoacyl-CoA 
thiolase (ACAA1) is a peroxisomal enzyme responsible for the β-oxidation of very 
long chain fatty acids (VLCFAs) [48]. In RCDP patients this enzyme was described 
as being present in the cytosol of fibroblasts and liver cells in its precursor, non-
cleaved and inactive form [49]. However, these patients did not exhibit VLCFA 
accumulation, indicating that the residual β-oxidation was sufficient to avoid in 
vivo VLCFA accumulation [49].  Furthermore, a diet dependent accumulation of 
phytanic acid is observed in RCDP patients due to the impaired action of 
phytanoyl-CoA hydroxylase (PhyH) [41] which is also a PTS2 carrying protein. 
Finally, Agps, which is also a PTS2 carrying protein [50], is mistargeted in RCDP 
type 1 patients resulting in a deficiency in the biosynthesis of plasmalogens [51].  
RCDP type 2 presents a defect in a single peroxisomal enzyme due to 
mutations in the gene that encodes the first enzyme in the plasmalogens 
biosynthetic pathway - Gnpat - leading to a single defect in plasmalogen synthesis 
[52]. 
RCDP type 3 exhibits mutated forms of the gene that encodes de enzyme 
that performs the second step in the plasmalogen biosynthetic pathway – Agps – 
leading also to a single defect in plasmalogens biosynthesis [53], [54]. 
Despite having different genetic causes, comparisons of clinical 
presentations and pathology among these three variants of RCDP showed little 
differences, indicating that the defects observed may be mainly due to the 
deficiency in plasmalogens. 
Some other human degenerative diseases have also been referred as 
having altered plasmalogen levels although they are not peroxisomal disorders. 
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There is still not a full knowledge about the importance of these changes, raising 
the question if the plasmalogen metabolizing products contribute to the 
pathology or if the decreased levels of plasmalogens are due to pathology 
associated conditions [2].   
 
 
ALZHEIMER’S DISEASE (AD) 
AD is a neurodegenerative disease and the most common form of 
dementia. It was shown in post-mortem brains from AD patients that the 
plasmalogen levels were decreased [55]. Several hypotheses have been put 
forward to explain the decrease of these ether phospholipids. On one hand, 
plasmalogens act as antioxidants and the high oxidative environment in AD 
increases the propensity of the vinyl-ether bond of plasmalogens to oxidative 
attack decreasing their physiological concentration. On the other hand, activation 
of psPLA2 may also contribute to the reduction of plasmalogen levels [24]. In 
addition, the described peroxisomal defect in AD may also cause plasmalogen 
defects [56] through its biosynthesis impairment. Despite all the factors, one 
cannot say if plasmalogen deficiency is a cause or a consequence in AD. 
 
 
NIEMANN PICK TYPE C DISEASE (NPC) 
NPC is a lisosomal storage disease characterized by an accumulation of 
unesterified cholesterol, glycosphingolipids and sphingomyelin with central 
nervous system (CNS) neurodegeneration [57]. It is caused by mutations in the 
genes NPC1 and NPC2 that are thought to be involved in the transport of 
cholesterol from endosomes to several intracellular destinations [5]. Experiments 
done with NPC mouse models demonstrated impairments in peroxisomal 
activities and decreased plasmalogen levels before the onset of the disease 
indicating that these events play a role in the initiation of the disease [58]. 
 
Other human disorders have been described as having plasmalogen levels 
decreased such as Down Syndrome, Neuronal Ceroid Lipofuscinosis which is an 
inherited neurodegenerative disorder with lipopigments accumulation in the 
lysosomal compartment, and Retinitis Pigmentosa, a X-linked and dominant and 
recessive autosomal disorder characterized by photoreceptor degeneration [3].  
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Plasmalogens form, thus, a strict relationship with several diseases, not 
only the ones related directly with its biosynthesis but also with others, such as 
neurodegenerative and metabolic disorders. This suggests an involvement of 
plasmalogens in the pathology of these diseases. 
 
 
 
PLASMALOGEN DEFICIENT MICE MODELS 
 
 In order to evaluate the biochemical and phenotypic consequences of 
plasmalogen deficiency, different mouse models have been created to mimic the 
human disorders that are originated from this ether-phospholipid deficient 
synthesis. Currently, four different mouse models with defects in ether-
phospholipids are available, i.e., the Pex7 KO mouse [35], the Pex7 hypomorphic 
mouse [59], the Gnpat KO [34] and the Agps hypomorphic mouse [60]. In this 
work two of these four mouse models were used: Pex7 KO and Gnpat KO mouse 
model. 
 
 
PEX7 KNOCKOUT MOUSE MODEL 
The Pex7 KO mouse model was generated by Brites et al. [35] by deleting 
the exon 3 of the Pex7 gene using homologous recombination and is used to 
mimic RCDP type 1. The deletion of Pex7 gene does not cause embryonic 
lethality. This way, Pex7 KO mice are born alive. However, they present a 
mortality rate of approximately 50% in the first 24h which may be explained by 
some of the phenotypic features of this mouse model such as hypotonia and 
decreased mobility which would hamper the feeding process. Animals that 
subsist this critical period after birth, survive to adulthood being able to reach 18 
months of age.  
As physical aspects, these mice exhibit dwarfism and phenotypically they 
also present testicular atrophy, eye cataracts and infertility [35]. Biochemically, in 
the Pex7 knockout mouse model all proteins containing PTS2 fail in being 
imported to the peroxisome. ADHAP-S, the enzyme catalysing the second step in 
the plasmalogen biosynthetic pathway is an example of PTS2 carrying protein and 
when trapped in the cytosol suffers proteolytic degradation [5]. This way, the 
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plasmalogen biosynthetic pathway is impaired in Pex7 KO mice. Moreover, these 
mice exhibit a defective peroxisomal fatty acid β-oxidation and increased levels of 
VLCFAs in newborn pups that are normalized in adulthood. The α-oxidation is 
also impaired due to a mislocalization of PhyH [35]. 
Pex7 KO mice reveal also a deficiency in neuronal migration demonstrated 
by studies performed in the developing brain at E18.5 where the density of 
neurons in the intermediate zone of the neocortex was increased. Another 
physiological defect presented by Pex7 KO mice is the endochondral ossification 
process. Newborn pups exhibit an incomplete skull ossification and defects in the 
ossification of several cartilage based structures, hindlimbs and middle phalanges 
[35]. 
  
 
GNPAT KNOCKOUT MOUSE MODEL 
 The Gnpat KO mouse model was generated by Rodemer et al. [34] by 
deleting exon 5 to 7 of the GNPAT gene  using homologous recombination and is 
used to mimic RCDP type 2. In Gnpat KO mice, there was described some 
embryonic lethality and a decreased lifespan (about 40% died within the first 6 
weeks of age). Similarly with Pex7 KO mice, Gnpat KO animals that subsist the 
period after birth, survive to adulthood and reach also the 18 months of age. 
Interestingly, in this animal model, the majority of the long lived animals were 
females, indicating a disproportional death rate between genders [34]. 
 Physically, Gnpat KO mice present dwarfism, shortening of the proximal 
limbs and are underweight. Moreover, male Gnpat KO mice are infertile in which 
adult testes are atrophic and spermatozoa are absent in the epididymis. Fertility 
problems exist also in female Gnpat KO mice. Physiologically, these animals 
exhibit also ocular abnormalities, namely cataracts and abnormal myelination in 
the optic nerve[34]. Biochemically, this mouse model does not produce Gnpat 
protein and consequently there is no measurable activity of this enzyme despite 
normal activities of Agps [34]. 
 This way, the single enzyme mutation leading to a single plasmalogen 
deficiency may be an advantage for a more straightforward understanding 
between the biochemistry-pathology relationship. 
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PERIPHERAL NERVOUS SYSTEM MYELIN SYNTHESIS AND STRUCTURE 
 
 Glial cells and neurons are in a continuous and highly regulated 
bidirectional dialog. The myelination process is one example of this 
intercommunication where, in the central nervous system (CNS) the 
oligodendrocytes, and in the peripheral nervous system (PNS) the Schwann cells 
(SCs) are responsible for communicating with axons and proceed with myelin 
synthesis and maintenance [61]. 
 Several neurological disorders such as leukodystrophies and peripheral 
neuropathies are a reflection of an impairment in the myelination process or of 
myelin degeneration. 
One should keep in mind that, regarding its biochemical composition, 
myelin contains a very high lipid-protein ratio in which 70-80% of the myelin 
composition consists in lipids and 20-30% is protein. Amongst others, this 
characteristic provides myelin its insulating property necessary for the saltatory 
propagation of nervous impulse [62].  
 
 
SCHWANN CELL AND PNS MYELIN SYNTHESIS 
   
 Schwann cells are derived from the neural crest [63]. At a very initial stage 
they derive from neural crest cells and evolve to a first intermediate stage in the 
SCs development process – the Schwann cell precursor – that is found in mouse at 
the embryonic day E12 and E13 (Figure 4). The second intermediate – Immature 
Schwann cell – is a product of evolution from the SC precursor stage and appears 
at E15 till the time of birth. Finally, around birth, and at the end of the 
development process, immature SCs start to generate the first myelinating SCs 
and subsequently the non-myelinating SCs. This way, SCs appear in the mature 
PNS as two different types of cells: the myelinating SCs which surround large 
axons and the non-myelinating SCs which engage smaller axons [64], [65], 
forming the Remak bundle. 
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Figure 4. The Schwann cell development process in mouse, schematic illustration of the main cell 
types and developmental transitions in Schwann cell . There are three major transient cell populations 
in the Schwann cell lineage in the embryonic phase. The neural crest cells that originate the second cell 
population – Schwann cell precursors – and the third cell population, the immature Schwann cell that is 
the one that precedes the transition where myelinating or non-myelinating Schwann cells are formed. 
SCs that engulf large-diameter axons will be stimulated to myelinate and SCs that ensheath small-
diameter axons evolve to mature non-myelinating Schwann cells. Note the reversible characteristic in the 
Schwann cell myelinating or non-myelinating stage demarcated by stippled arrows, which in part is 
responsible for the amazing ability of the PNS to regenerate. From [64], [65]. 
 
 
In the immature peripheral nerve, SCs engulf a large bundle of naked 
axons with varying diameters. The establishment of contact with these axons and 
the release of signals from the axons leads to  SC proliferation [66]. These signals 
from axons regulate also survival and differentiation of Schwann cells and are 
also involved in the determination of myelin thickness [67], [68]. As the SCs 
proliferate, they start to direct their processes deeper into the axon bundle 
starting a segregation process, known as radial sorting, which eventually leads to 
a one-to-one relationship between a SC and a axon segment to be myelinated 
[69]. Simultaneously, a basal lamina starts to be secreted by the SC at the 
abaxonal (outer) surface of the Schwann cell/axon unit. This basal lamina 
formation is intricately related with the myelination process since it is thought to 
be one of the events that leads to the SC differentiation towards myelination [62], 
[70], [71]. 
As mentioned above, axons have the capability to release certain types of 
signals that stimulate the SC to differentiate and myelinate. However, only axons 
with a minimum diameter size are able to secrete those signals. So, Schwann cells 
will only be able to form a myelin sheath if they become in contact with axons 
with a diameter greater than 0.7µm [62]. After the occurrence of this 
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communication, SCs are able to wrap their plasma membrane around axons and, 
this way, generate multiple layers of myelin and ultimately myelinate nerve fibres 
capable of producing the rapid saltatory impulse conduction of the nervous 
system. On the other hand, Schwann cells in contact with small-calibre axons will 
become non-myelinating Schwann cells, engulfing several axons and giving rise 
to the so called Remak bundles [72]. 
The presence of axons is not only required for the expression of the myelin 
genes during development but also for the maintenance of the myelinating 
phenotype since injury and loss of axonal contact leads to downregulation of 
myelin gene expression [62], SC dedifferentiation and myelin breakdown [73] as 
part of a process called Wallerian degeneration. However, SCs have a remarkable 
characteristic of reversibility between their non-myelinating and myelinating 
stages (Figure 4). For example, after injury and SC dedifferentiation, the 
phenotype of these SCs becomes very similar to the phenotype of immature SCs 
that precedes myelination leading to a favourable environment for axon regrowth. 
After contacting with these regrowing axons, SCs proceed to redifferentiation and 
myelination, performing the so called process of nerve regeneration [65], [74]. 
 
 
PNS AXONAL AND SCHWANN CELL STRUCTURE AND COMPOSITION 
 
 The myelinated fibers have a well-defined structure and can be divided into 
four structural regions according to their typical molecular distribution and 
protein expression: the Internode, the Juxtaparanode, the Paranode and the Node 
of Ranvier (Figure 5 B). 
The myelin sheath formed by the SC in the PNS enwraps the axon in 
segments that are separated by Nodes of Ranvier (Figure 5 A). These structures 
described as short, periodical interruptions in the myelin sheath are in the 
peripheral nerves covered by microvilli extensions of the Schwann cell (Figure 5 B) 
[67]. Regarding the regional expression of proteins, the node of Ranvier is 
characterized by a high abundance in Na
+
 channels essential in the action 
potential generation [75]. Other proteins particularly rich at the node are Ankyrin 
G [76] and the actin binding protein βIV Spectrin (Figure 5 C) [77].  
Adjacent to the node is a specialized region called paranode which is a 
non-compact myelin region characterized by the presence of a complex of two 
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cell-recognition molecules – contactin associated protein (Caspr) and contactin 
that are involved in the axo-glial junctions and play important roles in cell 
adhesion and intercellular communication [78]. Together with the paranode, the 
Schmidt Lanterman incisures (SLI) consist in the only regions of non-compact 
myelin in the myelinated axon. 
 
 
   
 
 
Figure 5. Structure of a PNS myelinated axon and the molecular composition in the different nodal 
regions. (A) Schwann cells in the PNS are responsible for myelination and enwrap several times the 
axonal segment forming the myelin sheath. Myelin covers the axon in defined segments forming the 
internode and leaving gaps – the nodes. (B) Longitudinal scheme of a myelinated fibre showing the 
different axonal regions. (C) Distinct expression of different molecules in the node and paranode. Na
+
 
channels, AnkyrinG and βIV Spectrin are typically nodal proteins. Caspr and Contactin are present in the 
paranodal region. Figure adapted from [67]. 
 
 
The Schwann cell is also characterized by a specific cytoarchitecture where 
it presents a highly polarized configuration, both radially and longitudinally, 
necessary for the propagation of action potential [79]. A specific complex of 
proteins, namely the dystroglycan-dystrophin complex, is necessary for the 
correct function of SCs in the myelination process, including the determination of 
A B 
C 
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the number of wraps that the SC performs around the axon and in the 
determination of the internodal length [80]. 
In the PNS, dystroglycan is present in the abaxonal membrane of the SC 
and whereas α-dystroglycan binds extracellular ligands such as laminin [81] and 
is anchored to β-dystroglycan, this latter one is a transmembrane protein in which 
its cytoplasmic tail interacts with cytoskeletal proteins namely f-actin [82]. 
The abaxonal Schwann cell membrane is compartmentalized into two 
distinct domains: the membrane covering the Cajal bands and the membrane 
directly apposed to the myelin sheath forming the appositions (Figure 6). 
Structurally, they differ in the way that in Cajal band compartment β-dystroglycan 
is cleaved  in its extracellular tail by a metalloproteinase and forms a complex 
with Utrophin and Actin, while in the apposition compartment, β-dystroglycan 
forms a intracellular complex with Periaxin and DRP2 (Dystrophin related protein) 
and binds extracellularly to α-dystroglycan (Figure 6) [83]. 
 
 
 
Figure 6. Schematic representation of the Schwann cell membrane compartments.  Two different 
compartments are formed in the abaxonal SC membrane: the apposition that is composed by a complex 
formed by α-dystroglycan bound to non-cleaved β-dystroglycan, DRP2 and Periaxin. On the other hand, 
the Cajal bands are composed of a complex formed by α-dystroglycan bound to cleaved β-dystroglycan, 
Utrophin or Dp116 and Actin allowing cytoskeletal organization. The scissors illustrate the 
metalloproteases action. Figure adapted from [84]. 
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REGULATION OF PNS MYELINATION – MOLECULAR MECHANISMS 
 
  Myelination process in the PNS is a highly regulated process that involves a 
bidirectional dialog between glial cells and neurons. This intercommunication is 
essential for myelin formation during development, myelin maintenance and also 
myelin regeneration after injury. While this axon-glia dialogue takes part, a 
healthy and functional nervous system is maintained [85]. 
Differentiation of neural crest cells to myelinating SCs requires the 
involvement of neuregulin-1 type III (NRG1-III), a key regulator involved in almost 
all aspects of the Schwann cell biology. NRG1-III produced by neurons in the CNS 
and PNS acts as a ligand that signals via tyrosine kinase receptors (ErbB2/ErbB3 
heterodimers) present in the SC membrane [86]. The release of NRG1 from the 
axon is the factor that determines myelin thickness and is proposed to be the 
responsible element for the fact that axons <1µM are not myelinated due to an 
insufficient amount of signalling molecule that is released. Myelin thickness is, 
this way, proportional to the axon diameter [87]. 
 According to Pereira et al. [88], there are three major signalling pathways 
involved in the PNS myelination process activated by NRG1-III. 
 One of the major pathways corresponds to the PI3K/PIP3/AKT/GSK3β 
signalling pathway [89]. Activation of this pathway by phosphorylation and 
activation of AKT leads to an activation of myelination. PTEN has an opposing 
effect over myelination through this pathway and inactivation of AKT experiments 
have shown to lead to hypomyelination [90].  
The second major pathway involves increase of intracellular Ca
2+
 by 
Phospholipase C-γ (PLC-γ) activation. This process leads to dephosphorylation and 
nuclear translocation of NFATc4 which will form a complex with Sox10 and 
activate the transcription of Krox20 and P0 pro-myelination genes [91]. Finally, 
the third pathway is the MEK pathway where the latter one phosphorylates Yy1. 
Yy1 will induce Krox20 which in its turn will induce myelination [92].  
 The SC myelination is under a very strict transcriptional control [93] (Figure 
7) which involves positive and negative transcription regulators. As examples of 
positive myelination regulators, there are Sox10 and Oct6 which have a 
synergistic effect in inducing the expression of Krox20. On the other hand, as 
negative myelination regulators, there are Sox2, c-Jun and Notch. Injury, 
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demyelination or disease lead to a dominant expression of negative transcription 
regulators of myelination [88]. 
 
 
 
Figure 7. Transcriptional regulation of myelination in the PNS. During embryonic development SCs 
evolve until reaching the immature SC stage in which they are organized in SC-axon families where they 
surround axon bundles. Next, SCs perform to radial sorting surrounding single axons >1µM of diameter 
reaching a one-to-one SC-axon relationship achieving the pro-myelinating SC stage. SCs that do not 
engulf single axons acquire a non-myelinating state in which they surround multiple small calibre axons 
forming the Remak bundles. The main positive transcription regulators of myelination are represented in 
blue and the most important transcription regulators are Sox10 which activates Oct6 and that together 
will induce Krox20. The latter one is the main regulator of the ensuing myelination program. The main 
negative transcription regulators of myelination are represented in white and yellow. They are typically 
under regulation of the positive regulators, however, upon nerve injury the negative regulators dominate 
and direct SC demyelination. Notch, c-Jun and Sox2 are the most important negative myelination 
regulators. Figure adapted from [88]. 
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PLASMALOGENS IN NERVOUS TISSUE 
 
 Given the enrichment of plasmalogens in the nervous tissue, it has been 
proposed that they have an important role in the normal function of neurons and 
myelinating glia. In fact, several studies involving cell lines of oligodendrocytes 
have described an enrichment of peroxisomes in these cells, associated to the 
necessity of lipid synthesis for myelin sheath assembly. Impairments in 
peroxisome assembly or function lead to myelin sheath degeneration and axonal 
loss [94][95]. In addition, the observation that several leukodystrophies and 
neurodegenerative diseases are characterized by defects in plasmalogens 
reinforces their importance for the normal function of the nervous tissue. In fact, 
studies performed in order to clarify the relationship between AD and 
plasmalogen have demonstrated that with the progression of the disease, the 
plasmalogen levels decrease [55]. There is still not sufficient evidence of whether 
the decreased levels of plasmalogens are a cause or a consequence of the 
disease, however, recent suggestions have been made relating the AD pathology 
to an inactivation Agps [96]. In AD pathological conditions the increase in ROS 
and Aβ peptide impairs the peroxisomal functions leading to a deficient import of 
Agps and plasmalogen biosynthesis blockade. Moreover, due to the elevated ROS 
values and due to the susceptibility of the vinyl ether bond in plasmalogens to 
suffer oxidation, plasmalogens levels in AD decrease [96]. 
 In RCDP patients, the primary defect in plasmalogens causes both neuronal 
and myelination defects. As such, the understanding and elucidation of the 
pathologies, mechanisms and players of the disease, is crucial for RCDP and the 
larger group of neurological disorders, which contain a secondary defect in 
plasmalogens, which may worsen the disease state and/or pathology. 
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The myelin sheath is of an extreme importance in biological organisms and 
plays innumerous crucial roles for the normal function of the nervous system. 
Among all of its functions, myelin is indispensable for a rapid conduction of the 
nervous impulse and functions also as a protective agent for the axon. The 
importance of the myelination process is highlighted by the presence of several 
pathological conditions derived by a progressive degeneration of the myelin 
sheath. 
 The main aims of this Master thesis were the determination of the 
importance of plasmalogens for the myelination process and the characterization 
of myelin’s structure and composition. In addition, we aimed at determining and 
characterizing the molecular mechanisms behind the severe pathology. Finally, an 
equally important goal of this work was the development of a therapeutic 
approach which would reveal itself effective in the prevention or improvement of 
the neuropathological consequences of a deficiency in plasmalogens. 
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ANIMAL HANDLING AND MOUSE MODELS 
 
 Mice were housed under specific pathogen-free conditions and all animal 
experiments were performed according to the guidelines of the Portuguese 
National Authority for Animal Health (DGV), the European Union directive 
2010/63/EU and according to the institutional rules. Animals were handled and 
experiments were performed by FELASA-accredited researchers. 
 
 
PEX7 AND GNPAT KNOCKOUT MICE MODELS 
 The Pex7 and Gnpat knockout mice used in all experiments were 
maintained on a Swiss-Webster background and obtained crossing heterozygous 
Pex7 or Gnpat breeding pairs. Wild-types (WT) are littermates from Pex7 and 
Gnpat knockout mice. Mice were maintained at 24±1ºC, at a 12h dark/light cycle 
and fed ad libitum. 
 Mouse genotyping was performed using genomic DNA extracted from ear 
clipping in the IBMC CCGen facility following the strategies previously developed 
[45], [97]. 
 
 
LICL TREATMENT 
 For the lithium chloride (LiCl) treatment, mice were injected 
subcutaneously with 50mg/kg of LiCl using a 30G needle. Two different setups (A 
and B) were performed according to the scheme of Figure 8. For the control 
condition, mice were injected with sodium chloride (NaCl) 50mg/kg. After 
treatment, mice were euthanized by decapitation and sciatic nerves as well as leg 
muscles were collected and frozen for further analysis (see below biochemical 
assessment). Furthermore, sciatic nerves were also collected and fixed for 
histological assessment as described below in Histological assessment of sciatic 
nerves.  
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Figure 8. Representative scheme describing the LiCl treatment strategy. Setup A consists in an every 
second day treatment from P7 to P15. At that day, Setup A LiCl treated mice were euthanized and tissues 
were collected for further analysis. Setup B consists in a daily treatment from P1 to P6. At P6, Setup B 
LiCl treated mice were euthanized and tissues were collected for further analysis. Control  animals 
treated with NaCl were subjected to the same setups. 
 
 
 
H ISTOLOGICAL ASSESSMENT OF SCIATIC NERVES 
 
SCIATIC NERVE FIXATION AND PROCESSING 
 Previously isolated sciatic nerves from 17 months old Pex7 knockout mice 
and correspondent WT littermates, as well as from LiCl and NaCl treated Gnpat 
knockout mice and correspondent WT littermates were processed for histological 
analysis. 
Sciatic nerves were fixed in glutaraldehyde (GTA) (4% of GTA in 0,1M of 
sodium cacodylate), post-fixed in osmium tetraoxide and embedded in epon for 
further processing to semi-thin and ultra-thin cross sections. Semi-thin cross 
sections of 1µm were stained with p-phenylenediamine (PPD) for g-ratio analysis 
and/or fibre density calculations. Ultra-thin cross-sections of 50nm of thickness 
were stained with uranyl acetate and lead citrate for electron microscopy (EM) 
analysis. 
 
 
MORPHOMETRIC ASSESSMENT OF SCIATIC NERVE FROM 17 MONTHS OLD MICE 
Using Photoshop software and 40x montage pictures of sciatic nerves from 
semi-thin cross-sections, fibre density was calculated counting all fibres in the 
nerve and dividing it by the nerve area. G-ratio evaluation was performed 
calculating the ratio between the axon diameter and the fibre diameter (includes 
the myelin sheath) and over 200 fibres in each cross-section of every animal were 
 
SETUP B 
Daily injections 
 
SETUP A 
Injections in alternating days 
1 DAY 2 15 8 7 6 
Setup A assessment Setup B assessment 
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analysed. Ultra-thin cross sections were assessed taking photographs at 8000x 
magnification in the transmission electron microscope (TEM Jeol JEM-1400) 
equipped with an Orius SC1000 Digital Camera. 
 
 
MORPHOMETRIC ASSESSMENT OF SCIATIC NERVE FROM LICL TREATED MICE 
Ultra-thin cross sections were analysed taking photographs at 5000x 
magnification in the transmission electron microscope (TEM Jeol JEM-1400) 
equipped with an Orius SC1000 Digital Camera.  
 
 
TEASED FIBERS 
 For the teased fibers experiments, the method of Court et al. [80] was 
followed. Mice were anesthetized with ketamine and medetomidine (100mg/kg 
and 1mg/kg respectively), euthanized and exsanguinated. Sciatic nerves were 
isolated and fixed with 4% Paraformaldehyde (PFA) in PBS. Under the dissection 
microscope and using 38G needles, the nerve was separated in several bundles 
(~0,5cm in length and as thin as possible). The bundles were blocked for 1hr at 
room temperature (RT) with 10% Normal Donkey Serum (NDS) and permeabilized 
with 10% NDS + 0.1% Triton. Immunofluorescence assay was done with primary 
antibody (see Table 2) over-night (O/N) at 4ºC and Alexa fluor secondary antibody 
for 2 hours at RT. The bundles were teased into single fibers in the silane-treated 
slides within a drop of Vectashield+DAPI. Afterwards, the slides were observed 
under the Epifluorescence microscope (AxioImager Z1 – Carl Zeiss Germany) and 
images of 20x and 63x magnification were taken in order to assess structural 
aspects of the fibers. Evaluation on the confocal microscope (Laser Scanning 
confocal microscope Leica TCS SP5 II) was also performed with 63x magnification 
pictures.  
 
 
IN VITRO MYELINATION ASSAY 
 
 Dorsal root ganglia (DRG) were collected from E13.5 (embryonic day 13.5) 
embryos and digested in 0.25% Trypsin-EDTA. Cells were plated in matrigel 
coated cover slides at a density of 6 DRGs per well and maintained at 37ºC. The 
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plating medium consists in DMEM high glucose with 2mM of L-glutamine, 10% 
FBS (Fetal bovine serum), 50ng/ml of NGF (nerve growth factor) and 1% P/S 
(Penicillin/Streptomycin). On the second day of culture, cells are put in a growing 
medium with Neurobasal, L-glutamine, NGF, Glucose 4g/L and B27 (gibco) during 
10 days. On the 11
th
 day of culture, cells are put in a myelinating medium with 
DMEM high glucose, L-glutamine, FBS, NGF and 50µg/ml of Ascorbic acid (AA) 
(Sigma) during 11 days. The culture is stopped on the 22
nd
 day of culture with 
fixation of cells with 4% PFA. Cells were permeabilized with 100% Methanol and 
blocked with 5% NDS for 1 hour at RT. Immunofluorescence assay was done with 
primary antibody (see Table 2) O/N at 4ºC and Alexa fluor secondary antibody for 
1 hour at RT (Figure 9).  
 
 
IN VITRO MYELINATION ASSAY WITH LICL TREATMENT 
For the in vitro LiCl treatment, a normal DRG explant culture for in vitro 
myelination assessment was performed. The administration of LiCl at a 
concentration of 16mM started on the 7
th
 day of culture and was always added on 
the days that the medium was changed. Together with LiCl, Forskolin at a 
concentration of 3µM was also added. 
 
 
 
 
Day 7: 
Initiation of the LiCl 
treatment 
Day 1: 
Cells put in 
culture in a 
medium with 
p/s. 
Day 2: 
Cells put in a growing / 
proliferating medium 
and changed every day. 
 
1 Day 
 
4 Days 
Day 6: 
Growing / proliferating 
medium changed every 
second day. 
 
5 Days 
Day 11: 
Cells put in a myelinating 
medium with ascorbic acid 
changed every second day. 
AA added every day. 
 
11 Days 
Day 22: 
Cell culture stopped. 
Immunofluorescence 
assay to MBP and βIII 
tubulin. 
Figure 9. Representative scheme of the in vitro myelination assay. DRG co-cultures were maintained 
for 22 days and assayed for immunofluorescence with βIII tubulin which stains neurites and MBP that 
marks myelinated segments. LiCl (or NaCl for controls) treatment is shown in grey with stippled arrows.  
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CELL CULTURE 
 
MOUSE EMBRYONIC FIBROBLASTS (MEFS) CULTURE 
 Mouse embryonic fibroblasts were collected from embryonic day 12. After 
removing heart, liver and all dark tissues, the remaining carcass was minced and 
trypsinized (Gibco 25300) at 37ºC for 10 min. Afterwards, single cell suspension 
was obtained by up and down using a 1000µl filter tip cut at the tip and 
posteriorly plated on T45 flasks with DMEM high Glucose, 10% FBS and 1% P/S. 
 
FBS STIMULATION OF MEFS 
Low passage number MEFs cultures in 3.5cm diameter culture dishes were 
allowed to grow until 80% confluence in a medium composed of DMEM high 
glucose, 10% FBS and 1% P/S. At this point, the cultures were subjected to serum 
starvation with medium containing 0.1% FBS for 12 hours. FBS induction was 
accomplished by adding medium containing 10% FBS and cells were incubated for 
0, 1, 3 and 5 minutes. After the incubation period, medium was quickly removed, 
and cells were washed with ice-cold PBS. Three independent experiments were 
performed. Lysates were prepared by adding ice-cold lysis buffer (see below in 
Biochemical Assessment the protein extraction buffer). Cells were scrapped with 
rubber policemen and collected into an eppendorf and placed on ice for further 
biochemical assessment through Western Blot (see Biochemical Assessment). 
 
 
BIOCHEMICAL ASSESSMENT 
 
SAMPLE PREPARATION AND WESTERN BLOTTING 
 Using sciatic nerves, leg muscle samples or MEFs, protein extraction was 
performed using a lysis buffer (PBS plus 0.3% Triton, 1x Complete Mini Protease 
inhibitor (Roche) and 1mM sodium orthovanadate). 
 Using a glass holder vial with ice water, tissues were sonicated (3 pulses of 
10 seconds, 35% cycle and 10% power) and centrifuged at 10000rpm for 5min at 
4ºC. Protein quantification was performed with the method of Lowry using a Bio-
Rad protein assay kit (BioRad DC Protein Assay) and optical density was measured 
at 750nm. 
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 Samples containing an equal amount of protein (25 µg) were run on 12.5% 
SDS PAGE gels and afterwards proteins were transferred to nitrocellulose 
membranes (Hybond™ ECL Amersham Biosciences). 
Blots were blocked in 5% NFDM (non-fat dry milk) in Tris buffer saline (TBS) 
with 0.1% Tween for 1hr at RT. Primary antibodies were diluted in 5% BSA (bovine 
serum albumin) in TBS with 0.1% Tween and incubated either for 1hr at room 
temperature or O/N at 4ºC depending on the antibody in question (see Table 2). 
Horseradish-Peroxidase conjugated Secondary antibodies were diluted in 5% 
NFDM in TBS with 0.1% Tween, used at a 1:5000 dilution and incubated for 1hr at 
RT. Immunodetection was performed by chemiluminescence, using ECL system 
Western Blotting detection reagents (Pierce western blotting substrate) and 
membranes were exposed to Amersham Hyperfilm ECL (GE Healthcare) and the 
film was developed. 
 Blots were scanned either on a Molecular Imager GS800 calibrated 
densitometer (Bio-Rad) or on a Epson Perfection 4490 Photo scanner and 
quantified using Quantity One 1-D Analysis Software v 4.6 (Bio-Rad). 
 
 
SUBCELLULAR FRACTIONATION 
 
 For the separation of different subcellular fractions, a Subcellular Proteome 
Extraction kit was used (539790 ProteoExtract® Subcellular Proteome Extraction 
kit – Millipore) that delivers four distinct protein fractions: fraction 1 (cytosolic 
fraction), fraction 2 (membrane/organelle protein fraction), fraction 3 (nucleic 
protein fraction) and fraction 4 (cytoskeletal fraction). 
Low passage number MEFs cultures in 3.5cm diameter culture dishes were 
allowed to grow until 80% confluence in a medium composed by DMEM high 
glucose, 10% FBS and 1% P/S. At this point, the starvation protocol previously 
described in FBS stimulation of MEFs was performed at three different time-
points: 0min, 3min and 5min. Subcellular fractionation protocol was performed 
according to the kit’s datasheet and the entire protocol was executed with the 
cells in gentle agitation and at 4ºC. 
Initially, cells were washed twice for 5min with Wash Buffer. The cells were 
then incubated for 10min with Extraction Buffer I. The resulting supernatant 
(Fraction 1) which contains proteins extracted from the cytosolic fraction was 
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transferred to an eppendorf. The remaining cellular material was incubated with 
Extraction Buffer II for 30min and the corresponding supernatant (Fraction II) 
contains membrane/organelle proteins. Extraction Buffer III together with a 
nuclease solution was incubated for 10min and fraction III containing nuclear 
proteins was gathered to its correspondent eppendorf. The remaining cellular 
material was finally incubated with Extraction Buffer IV leading to obtainment of 
Fraction IV containing cytoskeletal and matrix proteins. 
The different subcellular fractions were frozen for further biochemical 
assessment. 
 
 
STATISTICAL ANALYSIS 
 
 For statistical analysis the graphpad software was used and results were 
expressed as the mean ± s.e.m.. Comparison data between groups was 
performed using either Student’s t-test, one way ANOVA with Tukey’s post-test, 
or Mann Whitney test. p<0.05 was considered statistically significant. 
 
 
Table 2. Summarized list of antibodies used in this work. Includes information about the host, the 
purpose of the utilization of the antibody, its dilution and the supplier. 
ANTIBODY HOST PURPOSE/DILUTION SUPPLIER 
DRP2 Rabbit ICC / 1:300 Peter Brophy 
Caspr Rabbit ICC / 1:2000 Elior Peles 
βIII Tubulin Rabbit ICC / 1:600 Epitomics 
MBP Rat ICC / 1:250 Chemicon 
p-AKT (Ser473) Rabbit WB / 1:1000 Cell Signalling 
p-AKT (Thr308) Rabbit WB / 1:1000 Cell Signalling 
T-AKT Rabbit WB / 1:1000 Cell Signalling 
p-GSK3β (Ser9) Rabbit WB / 1:1000 Cell Signalling 
T-GSK3β Rabbit WB / 1:1000 Cell Signalling 
p-c-Raf Rabbit WB / 1:1000 Cell Signalling 
Caveolin Rabbit WB / 1:5000 Transduction Laboratories 
GAPDH Rabbit WB / 1:1000 Cell Signalling 
ACAA1 Rabbit WB / 1:1000 Sigma-Aldrich 
Tubulin Rabbit WB / 1:1000 Cell Signalling 
Sox 2 Rabbit WB / 1:1000 Abcam 
Oct 6 Rabbit WB / 1:1000 Abcam 
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Previous work at the Nerve Regeneration group has revealed that a 
plasmalogen deficiency affects the development and functioning of the peripheral 
nervous system (PNS) (Figure 10) [98]. Using Pex7 and Gnpat KO mice, it has been 
shown that a plasmalogen deficiency impairs: (i) the process of radial sorting, 
with a failure in the correct segregation of large calibre axons from axon bundles; 
(ii) myelination, as plasmalogen-deficient mice have increased g-ratio during the 
first 4 weeks of postnatal development of the PNS; and (iii) nerve conduction, with 
increased latencies of compound muscle action potentials. Given these 
observations, the aims of this Thesis were to elucidate the defects in myelination 
and myelin maintenance and unravel the mechanisms behind the neuropathy 
caused by a deficiency in plasmalogens.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
  
 
P10 P80 
 
 
Impaired radial sorting 
 
Impaired myelin compaction 
 
Impaired initial myelination process 
Figure 10. Consequences of plasmalogen deficiency to PNS. Plasmalogen deficient mouse models 
(Pex7 KO and Gnpat KO) have been used to assess the pathology caused by the absence of these ether-
phospholipids. During the lifespan of mice, plasmalogens contribute to the myelination process in 
different ways and timepoints. On a very initial stage of the myelination process, a plasmalogen 
deficiency causes both impaired radial sorting (lower panel, left) and impaired myelination. However, in 
adult mice, the defect in myelination is rescued (upper panel), although x-ray diffraction analyses 
showed that myelin devoid of plasmalogens is less compact (lower panel, right).  
KO WT 
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DEMYELINATION IN THE ABSENCE OF PLASMALOGENS 
 
As adult plasmalogen-deficient mice showed normal myelination we 
hypothesized that given the initial hypomyelination the formation and/or 
maintenance of myelin would be impaired.  
The phenotypic characterization of Pex7 and Gnpat KO mice, supported 
our hypothesis, as mice older than 1 year acquired a progressive neuropathy with 
tremors and generalized ataxia, leading to hindlimb paralysis. We evaluated nerve 
pathology in Pex7 and Gnpat KO mice that reached the humane end point 
(around the age of 17±1.9 months). Histological analysis of sciatic nerve sections 
stained with PPD showed that in comparison with WT nerves, nerves from Pex7 
KO mice presented a pronounced demyelination and loss of myelinated fibers 
(Figure 11 A and B).  
 
 
 
 
 
 
WT Pex7 KO 
A 
B 
Figure 11. Deficiency in myelin maintenance in the absence of plasmalogens demonstrated by an 
age-dependent demyelination. Semi-thin cross-sections of sciatic nerves from 17 months old WT and 
Pex7 knockout mice were stained with PPD to enable the visualization of myelin. Panels in A correspond 
to 10x montage pictures and panels in B represent the corresponding sciatic nerve from the overhead 
panel at a 40x magnification. Nerves from Pex7 KO mice have a striking visible pathology comprised of 
loss of myelinated fibers and loss of myelin. 
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A similar pathology was observed in nerves from aged Gnpat KO mice (data 
not shown). Quantifications revealed a 2-fold decrease in the density of 
myelinated fibers in Pex7 KO nerves (Figure 12 A). The determination of the g-
ratio, confirmed the demyelination status of nerves from KO mice but it also 
revealed that myelin loss was predominant in large-calibre axons, as axons with a 
diameter smaller than 3µm had normal g-ratio (Figure 12 B). 
 
 
 
Figure 12. Absence of plasmalogens leads to axon loss and demyelination. The density of myelinated 
fibers decreases in aged Pex7 KO mice (A) and g-ratio values show that, in the absence of plasmalogens, 
with an increasing axon diameter, g-ratio increases (B). WT n=4 and KO n=5. For g-ratio evaluation over 
200 MF were assessed. Statistical analysis was performed using Student’s T-test. Error bars show s.e.m. 
and * = p < 0.02. 
 
 
The results obtained with the histological analysis warranted a more 
detailed ultrastructural analysis, to unravel the extent of the demyelination and 
determine if the observed loss of myelinated fibers was due to complete lack of 
myelin as completely demyelinated axons are not stained with PPD or due to an 
actual loss of axons. The electron microscopic analysis, revealed a striking 
pathology in the nerves from aged Pex7 KO mice (Figure 13). Axonal loss was 
evident in mutant nerves, with reduced number of axons regardless of the 
myelination status. Nevertheless, the lack of plasmalogens had a profound effect 
in Schwann cells, as we observed completely demyelinated axons (left fibre with 
asterisk), severely demyelinating axons (right fibre with asterisk), and possibly 
remyelinating axons (middle fibre with asterisk). In mutant nerves, we observed 
signs of remyelination as small calibre axons had normal g-ratio (Figure 12) and 
the electron microscopy analysis also indicated that these small calibre axons 
contained normal myelin. In addition, we observed that the endoneurium of 
A B 
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mutant nerves is filled with Schwann cell processes (arrows). These processes 
seemed to represent failed attempts of Schwann cells to remyelinate 
demyelinated or demyelinating axons. The Schwann cells act to the demyelination 
by extending process to wrap axons in order to attempt remyelination. The 
failure in accomplishing this, coupled with the excessive production of the 
processes creates the appearance of structures similar to onion-blubs, which 
consist in the formation of redundant basal lamina and are the hallmark signs of 
failure in remyelination. Nevertheless, we also observed Schwann cell processes 
around unmyelinated axons in Remak bundles, suggesting that the mutant 
phenotype in Schwann cells from KO mice may also be unrelated to myelination. 
 Combined, our results demonstrate that the deficiency in plasmalogens 
severely affects Schwann cells and myelination. Given the extent of demyelination 
during aging and the evidences for failure in remyelination, we hypothesize that 
the axonal loss is secondary to the demyelination. 
  
 
 
Figure 13. Sciatic nerves from plasmalogen deficient mice exhibit axon loss, demyelination and 
failure to remyelinate. Electron microscopy assessment of nerves from Pex7 KO mice showed clear 
signs of demyelination, with axons lacking (left asterisk) or containing considerable less myelin (right 
asterisk) and the formation of Schwann cell processes (arrows). Scale bar = 2µm.  
   
WT Pex7 KO 
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D ISORGANIZED MYELIN IN THE ABSENCE OF PLASMALOGENS 
 
The preceding results, combined with the previous characterization of the 
myelination process presented in Figure 10, indicate that the functions and roles 
of Schwann cells are severely compromised in a plasmalogen deficiency. This 
way, we hypothesised that despite the observation of normal g-ratio in nerves 
from adult plasmalogen-deficient mice, the deficiency could affect the structure 
and organization of the myelinating Schwann cell.  
 In order to analyse the structure and organization of myelinated fibers, we 
performed immunofluorescence in teased fibers, to determine the pattern and 
levels of proteins that function as markers for distinct regions of a given 
myelinated fibre. Antibodies against Caspr were used to label the axonal 
paranode, antibodies against DRP2 were used to label the Schwann cell 
appositions, and Phalloidin, which labels f-actin, was used to stain non-compact 
myelin.  
 
 
    
   
Figure 14. Myelin structure and composition is altered in the absence of Plasmalogens.  Epi-
fluorescence microscope images of Caspr and Phalloidin show that, compared with WT, adult Pex7 KO 
mice exhibit an altered paranode assembly demarked with Caspr and contain an increased number of 
Schmidt Lanterman incisures demarked with Phalloidin. Upper panel pictures are at a 63x magnification 
and lower panel pictures are at a 20x magnification. 
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Caspr labelling in teased fibers from WT nerves, revealed the paranodal 
region (Figure 14, upper panel). However, we observed a less demarked 
paranodal region and a more diffused staining in teased fibers from Pex7 KO 
mice, suggesting a defective recruitment of Caspr to this axonal region due to a 
defective paranodal assembly. Phalloidin staining was performed in order to 
assess the cytoskeletal organization of the myelinating Schwann cells. By staining 
for f-actin we could visualize the Schmidt-Lanterman incisures, which are regions 
of non-compact myelin involved in metabolic processes of the myelin sheath and 
communication across the myelin sheets which are vital to myelin function 
[99][100][101]. Our analysis revealed an increase in the number of Schmidt-
Lanterman incisures in teased fibers from Pex7 KO nerves (Figure 14, lower 
panel). Combined with the observations using X-ray diffraction that showed larger 
myelin periodicity in sciatic nerves from Pex7 KO mice (Figure 10) [98], our 
results indicate that, in general, plasmalogen-deficient myelin is less compact.  
 
 
 
Figure 15. Plasmalogen deficiency leads to abnormal myelin in structure. Confocal analyses of f-actin 
and DRP2 in nerves from Gnpat KO mice demonstrated an increase in the number of SLI (upper panel) 
demarked with Phalloidin (f-actin) and an abnormal compartmentalization of the Schwann cell’s plasma 
membrane (lower panel) demarked with DRP2. Scale bar is 10µm. 
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DRP2 immunolabeling was performed to assess the compartmentalization 
of the cytoplasm from Schwann cells. Our analysis revealed a fragmented and 
disorganized pattern of DRP2 labelling in Pex7 KO nerves indicative of a 
disorganization of the appositions and abnormal compartmentalization of the 
SC’s plasma membrane. In order to corroborate that the abnormalities found in 
Pex7 KO nerves were solely due to the defects in plasmalogens, we also analysed 
teased fibers from Gnpat KO mice. For this, we used 9 months old mice as not to 
use mice within ongoing demyelination. Our analyses (Figure 15) using f-actin 
and DRP2 staining revealed that the lack of plasmalogens causes an increase in 
the number of Schmidt-Lanterman incisures and disorganized appositions. 
Combined, our results showed that plasmalogen-deficient nerves are 
initially characterized by hypomyelination, and that despite reaching normal 
amounts of myelin (normal g-ratio), they are dysmyelinated and acquired a 
progressive and severe demyelination. 
 
 
 
DEFECTIVE MYELINATION IN THE ABSENCE OF PLASMALOGENS 
 
 Given the complexity of the myelination process and the different defects 
observed in plasmalogen-deficient nerves, we performed in vitro myelination 
assays to assess the role of plasmalogens in myelination with another type of 
approach besides g-ratio determination, and without confounding effects 
including delays in development. 
 in vitro myelination assays were performed according to well described 
strategies [102], [103]. DRG co-cultures of neurons and Schwann cells from E13.5 
embryos were maintained in culture for 22 days and stimulated to myelinate for 
the last 11 days by the addition of ascorbic acid. Immunofluorescence assays for 
βIII tubulin allowed the evaluation of neurite growth, density and viability. When 
comparing WT with Gnpat KO co-cultures, there was no observable difference in 
neurites (Figure 16 A, left panel), as plasmalogen deficient DRG neurons are able 
to produce a normal grid of neurites. However, when assessing by 
immunofluorescence staining of myelin basic protein (MBP), which marks 
myelinated segments and allows the evaluation of the myelination status of the 
cultures, the results were quite different. Gnpat KO co-cultures exhibited a 
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notable impairment in the myelination process demonstrated by the MBP 
immunolabeling (Figure 16 A, right panel). 
  
 
  
 
 
 
 
       
Figure 16. Defective in vitro myelination in the absence of plasmalogens. Results from in vitro 
myelination assays with DRG co-cultures from WT and Gnpat KO mice revealed no differences in the 
formation of a neurite network, as judged by immunolabeling with anti-tubulin-βIII (green labelling in A). 
Assessment of myelination by MBP immunolabeling revealed fewer and shorter myelin segments in co-
cultures from Gnpat KO mice (red labelling in A). Quantifications of density (B) and length (C) of myelin 
segments, confirmed the immunohistological analyses, with a decreased number and length of 
myelinated fibers. Quantification of the paranodal length (D) also showed that in Gnpat KO co-cultures 
the distance between two adjacent myelinated segments is increased. Statistical analysis was performed 
using Student’s T-test. Error bars show s.e.m. and * = p < 0.03. 
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 Further analysis was performed in order to obtain not only qualitative 
information but also a quantitative assessment of the degree of impairment in the 
myelination process. The number and size of myelinated segments was 
determined, as well as, the paranodal length (the distance between two adjacent 
myelin segments). The results showed a drastic decrease in the number of myelin 
segments (Figure 16 B). In addition, the length of myelinated segments was also 
assessed and the absence of plasmalogen affected this feature in which Gnpat KO 
mice exhibited shorter myelinated segments (Figure 16 C) and an increase in the 
paranodal distance (Figure 16 D). The latter observation corroborated the results 
obtained with Caspr labelling in teased fibers, indicating a defect in nodal 
assembly. 
 
 
 
IMPAIRED SIGNALLING PATHWAYS DURING MYELINATION PROCESS 
 
 With the detailed characterization of the neuropathy caused by the 
deficiency in plasmalogens, we aimed at understanding the mechanisms behind 
the pathology. Based on the phenotype and pathology we decided to study the 
expression levels of several kinases in 15-day old WT and Gnpat KO mice. The 
choice of age was a compromise between younger ages, in which we may not 
have sufficient material from individual mice, and older ages, in which the peak of 
the signalling pathways involved in radial sorting and myelination has passed. 
 The expression levels of phosphorylated (active) ERK1/2, AKT, JNK and 
STAT-3 were evaluated by western blot. The levels of phosphorylated ERK1/2, JNK 
and STAT-3 in sciatic nerve lysates from Gnpat KO mice were similar to those of 
WT nerves (Figure 17). Nevertheless, we found that the levels of phosphorylated 
AKT (at Ser473 and Thr308) were significantly reduced in nerve lysates from 
Gnpat KO mice (Figure 18 A). To determine if the reduction in active AKT, would 
impact on the phosphorylation of its targets we analysed the expression of 
phosphorylated GSK3β and c-Raf. The levels of phosphorylated GSK3β at Ser9 
(Figure 18 B) and phosphorylated c-RAF at Ser259 (Figure 18 C), were reduced in 
nerve lysates from Gnpat KO mice. Combined, these results indicate that in sciatic 
nerves from P15 Gnpat KO mice, there is an impairment in AKT-mediated 
signalling.  
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Figure 17. Plasmalogen deficiency does not affect the activation of JNK, STAT3 and ERK1/2. Sciatic 
nerve lysates from P15 WT and Gnpat KO mice were analyzed by Western Blot for the expression of 
phosphorylated forms of JNK, STAT3 and ERK1/2. When compared with WT, plasmalogen deficient mice 
did not exhibit alterations in the phosphorylation status of these three kinases . Error bars show s.e.m. 
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Figure 18. Plasmalogen deficient mice show an altered phosphorylation status of AKT and two of 
its downstream targets, GSK3β and c-RAF. Sciatic nerve lysates from P15 WT and Gnpat KO mice were 
analyzed by Western Blot for the expression of phosphorylated forms of AKT, GSK3β and c-RAF. Both 
phosphorylated forms of AKT (Ser473 and Thr308) were decreased as well as GSK3β phosphorylated in 
the Ser9 and c-RAF phosphorylated in the Ser259. Statistical analysis was performed using Students T-
test. Error bars show s.e.m. and * = p < 0.05. 
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Of interest, is the observation that impaired AKT activation, leads to 
reduced levels of GSK3β phosphorylated at Ser9. Previously, it has been shown 
that upon phosphorylation and activation AKT phosphorylates GSK3β at Ser9, 
rendering GSK3β inactive. This inactivation of GSK3β is crucial during the process 
of myelination as it is necessary to allow the transition of Schwann cells from 
immature to pro-myelinating, in the processes of radial sorting and initiation of 
myelin formation [89]. As such, our results seem to explain the pathological 
findings in nerves from Gnpat KO mice and place AKT and GSK3β as potential 
targets and/or effectors in a plasmalogen deficiency. 
 
 
 
DEFICIENT AKT PATHWAY ACTIVATION IN PLASMALOGEN ABSENCE 
 
 Given that plasmalogen-deficient nerves have an impaired activation of AKT 
and an impaired AKT-mediated signalling cascade, we next aimed at 
characterizing in more detail the defect in the AKT activation. 
 To determine if the defect in AKT activation was cell specific and/or 
specific to a given receptor or a specific signalling cascade, we investigated if 
mouse embryonic fibroblasts (MEFs) from WT and Gnpat KO mice, would respond 
similarly to serum stimulation [104]. For this, MEFs were starved O/N and then 
stimulated with 10% FBS for 0, 1, 3 and 5minutes. In WT MEFs, AKT activation was 
time dependent, reaching a maximal response after 5 min of FBS stimulation 
(Figure 19 A). However, in plasmalogen-deficient MEFs we observed a defective 
activation of AKT, with reduced levels of phosphorylation at Ser473 and Thr308 
(Figure 19 B and C). The impairment in AKT activation seems specific as the FBS 
stimulus is able to normally activate ERK1/2 in MEFs from Gnpat KO mice (Figure 
19 D and E).  
Combined, these results indicated that regardless of the cell type and 
stimuli, a deficiency in plasmalogens results in a specific impairment in AKT 
phosphorylation. 
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Figure 19. Absence of Plasmalogens interferes with AKT activation in Gnpat KO MEFs. Serum-
starved WT and Gnpat KO MEFs were stimulated with 10% FBS for 0, 1, 3 and 5 min. Lysates were 
prepared from each individual point and western blot analysis of AKT phosphorylation  was performed 
(A). For the quantification of phosphorylated levels of AKT, averaged values of 3 independent 
experiments are shown as percentage of the maximal levels of phosphorylation found in WT MEFs (B, C). 
As control we determined the degree of ERK1/2 phosphorylation after FBS stimulation (D, E). Statistical 
analysis was performed using Mann-Whitney test, and significant P values are shown above bars. Error 
bars show s.e.m. 
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LACK OF PLASMALOGENS IMPAIRS MEMBRANE RECRUITMENT OF AKT 
 
AKT activation requires the phosphorylation of Ser473 and of Thr308, but 
for this phosphorylation to occur, AKT must be recruited to the plasma 
membrane [105]. Given that we observed that a plasmalogen deficiency impairs 
AKT activation in a cell/tissue- and stimuli-independent manner, we hypothesized 
that the reduced phosphorylation and activation of AKT in plasmalogen-deficient 
cells could be due to an impairment in AKT recruitment to the plasma membrane. 
  
 
   
Figure 20. Plasmalogen deficiency leads to impaired recruitment of AKT to the plasma membrane. 
Serum-starved WT and Gnpat KO MEFs were stimulated with 10% FBS for 0, 3 and 5 min. Lysates were 
prepared from each individual point and western blot analysis of AKT phosphorylation  was performed 
(A). Additionally, three different intracellular markers were analysed to evaluate the purity of the 
fractions: Caveolin, GAPDH and ACAA1. For the quantification of phosphorylated levels of AKT, averaged 
values of 3 independent experiments are shown as percentage of the maximal levels of phosphorylation 
found in WT MEFs (B, C). Statistical analysis was performed using Mann-Whitney test, and significant P 
values are shown above bars. Error bars show s.e.m.     
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Using MEFs from WT and Gnpat KO mice and FBS stimulation setup, we 
performed differential permeabilization and extraction of proteins to obtain 
different subcellular fractions. Serum starved MEFs were stimulated with 10% FBS 
for 0, 3 and 5min, and lysates from these time points were used to analyse AKT 
phosphorylation in cytosolic and membrane fractions (Figure 20 A). In WT MEFs 
we observed the time-dependent increase in the phosphorylated forms of AKT in 
the cytosolic and membrane fractions (Figure 20 B and C).  
However, in Gnpat KO MEFs, we observed reduced levels of membrane-
associated AKT and reduced AKT phosphorylation in both cytosolic and 
membrane fractions (Figure 20 B and C). To control for purity of the fractions and 
the strength of differential extraction, we analysed the levels of caveolin-1 (a 
membrane marker), GAPDH (a cytosolic marker) and ACAA1 (a peroxisomal 
marker) (Figure 18A). The presence of caveolin-1 and GAPDH in their 
corresponding fractions confirmed the ability of the differential protein 
extraction. In addition, and given that AKT is weakly associated with the plasma 
membrane, we verified that the extraction performed to obtain the cytosolic 
proteins would not interfere with membrane solubilization (that could release 
proteins that are weakly associated with membranes). The localization of ACAA1, 
a peroxisomal protein localized to the matrix of the organelle, was restricted to 
the membrane fractions (Figure 20 A), indicating that the extraction of cytosolic 
proteins does not have enough strength to interfere with proteins loosely 
associated with membranes. 
 
 
 
INHIBITION OF GSK3β RESCUES PNS  DEFECTS OF PLASMALOGEN-
DEFICIENCY 
 
The characterization of the mechanism behind the deficiency in 
plasmalogens, revealing that AKT-mediated signalling is impaired in nerves from 
Gnpat KO mice, allowed us to devise and test a potential therapeutic intervention. 
Given that GSK3β is a known negative regulator of Schwann cell differentiation 
and myelination, and that we found decreased levels of the inactive form of 
GSK3β (phosphorylated at Ser9), we hypothesized that pharmacological or 
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chemical inhibition of GSK3β would be able to improve the impaired processes of 
mutant Schwann cells. 
Lithium chloride (LiCl) is a well known inhibitor of GSK3β, and is currently 
used for the treatment of bipolar disorders and mood alterations [106], [107]. 
The mechanism of action of LiCl in the inhibition of GSK3β is rather complex 
[108], as it may act directly on GSK3β or preventing the dephosphorylation of AKT 
by protein phosphatase 2A [109]. Therefore we first determined if the in vitro 
defect in myelination observed in co-cultures of Gnpat KO mice, could be 
modulated by LiCl. DRG co-cultures of neurons and Schwann cells were prepared 
from WT and Gnpat KO mice, and LiCl was added to the culture 4 days before the 
initiation of myelination, as not to interfere with neurite formation or growth.  
Comparing to the control treatment (16mM NaCl), in which we observe a 
striking myelination defect in Gnpat KO co-cultures, the addition of LiCl was able 
to completely rescue myelination in the absence of plasmalogens in which the co-
cultures presented an increase in the number of myelin positive segments (Figure 
21). 
 
 
Figure 21. LiCl treatment is able to revert the defect in myelination in plasmalogen deficient mice. 
Treatment with LiCl was able to rescue the myelination defect in DRG co-cultures of neurons and 
Schwann cells from Gnpat KO embryos. The degree of in vitro myelination was determined as the density 
of myelin segments (positive for MBP) 11 days after the daily addition of ascorbic acid in medium 
supplemented with 16mM NaCl (control) or with 16mM LiCl. Statistical analysis was performed using 
one-way ANOVA. Error bars show s.e.m. and * = p < 0.05. 
 
 
The results obtained showing a rescue of in vitro myelination with addition 
of LiCl, prompted the determination if in vivo treatment with LiCl could also lead 
to an improvement or rescue of the pathology. We devised 2 treatment schemes: 
on setup A, we initiated subcutaneous injections of LiCl at a dosage of 50mg/Kg 
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on alternating days from P7 to P15; on setup B, we initiated daily subcutaneous 
injections of LiCl at a dosage of 50mg/Kg from P1 to P6. 
   
 
   
  
 
   
Figure 22. LiCl restores AKT activation and GSK3β inhibition in Gnpat KO mice. Sciatic nerve lysates 
from P15 WT and Gnpat KO mice treated with LiCl were analyzed by Western Blot for the expression of 
phosphorylated forms of AKT and GSK3β. LiCl treatment according to setup A was able to restore AKT 
phosphorylation levels at both Ser473 and Thr308 (B-D). Moreover, inhibitory phosphorylation of GSK3β 
at Ser9 increased with LiCl treatment (E) and the active form of GSK3β phosphorylated at Tyr216 was 
decreased (F). Statistical analysis was performed using Mann-Whitney test and significant p values are 
shown above bars. Error bars show s.e.m. 
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Western blot analyses in nerve lysates from P15 mice treated according to 
setup A, revealed an increase in the phosphorylation levels of AKT in nerves from 
LiCl-treated Gnpat KO mice, that reached the levels observed in WT mice (Figure 
22 B to D). Concomitant with the increase in active AKT, we observed an increase 
in the inhibitory phosphorylation at Ser9 of GSK3β (Figure 22 E), and a decrease 
in the active form of GSK3β, i.e., GSK3β phosphorylated at Tyr216 (Figure 22 F). 
 Combined, these results suggested that LiCl treatment in Gnpat KO mice 
was able to rescue the biochemical and signalling defect caused by the lack of 
plasmalogens.  
Given that the treatment with LiCl was able to restore AKT-mediated 
signalling in plasmalogen-deficient nerves, we investigated if this would have 
beneficial outcomes during the period of axonal sorting, to rescue the observed 
defects in Gnpat KO mice. Western blot analyses in muscle lysates from P6 mice 
treated according to setup B, revealed an increase in the phosphorylated form of 
GSK3β at Ser9, indicative of AKT-mediated signalling activation and concomitant 
inactivation of GSK3β (Figure 23 B and C).  
 
 
 
Figure 23. LiCl treatment inactivates GSK3β in the period of axonal sorting. Muscle lysates from P6 
WT and Gnpat KO mice treated with LiCl were analyzed by Western Blot for the expression of 
phosphorylated form of GSK3β at Ser9. LiCl treatment according to setup B was able to inhibit GSK3β by 
increasing its phosphorylation at Ser9 (B, C). Statistical analysis was performed using Mann-Whitney test. 
Error bars show s.e.m. and * = p < 0.05 
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The treatment with LiCl was also able to restore Schwann cell 
differentiation in nerves from P6 Gnpat KO mice, as we observed a decrease in 
the levels of Sox2, a marker of immature Schwann cells (Figure 24 A) and an 
increase in Oct6, a marker of differentiated myelinating Schwann cells (Figure 24 
B). 
 
  
 
 
 
 
Given that our biochemical assessment indicated that the LiCl treatment 
was able to rescue the impaired signalling and the differentiation of the Schwann 
cell, we investigated if this improvement would have a beneficial outcome in 
terms of the pathophysiology of sciatic nerves from P6 mice (setup B). 
Ultrastructural analysis of sciatic nerves from control-treated and LiCl-treated 
Gnpat KO mice, revealed a striking effect of LiCl administration (Figure 25). 
Whereas nerves from control-treated KO mice, showed the characteristic 
hypomyelination, LiCl treatment, and in accordance with the levels of Oct6 (Figure 
24), was able to induce myelination and restore the histological appearance of 
sciatic nerves (Figure 25 A). 
In order to have a better assessment on the beneficial consequences of 
LiCl, we determine: 1- the number of axons per bundle, to evaluate if the 
treatment would rescue the defect in axonal sorting; and 2- the density of sorted 
axons/promyelinating Schwann cells, to evaluate the differentiation of Schwann 
cells.   
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Figure 24. LiCl treatment restores Schwann cell differentiation. Western Blot assays performed in 
sciatic nerves from Setup B treated mice exhibited decreased levels of Sox2 indicative of a reduction in 
the immature state of the nerve (A). Furthermore, Oct6 levels rose above the control conditions in both 
WT and Gnpat KO mice demonstrating increased levels of differentiated Schwann cells in the 
myelinating nerve (B). Statistical analysis was performed using Mann-Whitney test. Error bars show 
s.e.m. and * = p < 0.05. 
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Figure 25. LiCl treatment rescues radial sorting and myelination. Electron microscopy assessment of 
P6 Gnpat KO nerves treated with LiCl revealed an apparent recovery in the myelination (A). Further 
evaluation showed that LiCl treatment leads to a normalization in the number of axons per bundle (B) 
and in the density of sorted axons (C). Statistical analysis was performed using Student’s t-test and 
significant p values are shown above bars. Error bars show s.e.m. Scale bar = 5µm.  
 
 
The results obtained showed that upon LiCl treatment there was a 
normalization in the number of axons/bundle, since in sciatic nerves from LiCl-
treated mice there was a significant reduction in the number of these unsorted 
axons to normal values (Figure 25 B). In addition, we also observed a significant 
increase in the density of sorted axons, in LiCl-treated KO mice indicating a 
normal progression of Schwann cells from immature to pro-myelinating stage 
(Figure 25 C). 
Combined, the results demonstrate the efficacy of LiCl treatment in 
restoring the impaired signalling pathway, and in improving the development of 
mutant Schwann cells, which leads to a rescue in radial sorting and myelination.   
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Plasmalogens are a special class of phospholipids, as they contain a vinyl-
ether bond at the sn-1 position of the glycerol backbone [2], [3], [5]. This feature 
is thought to be responsible for some of the functions attributed to plasmalogens 
which include antioxidant properties and determinants of membrane fluidity [11], 
[29].  In addition, and due to their composition, plasmalogens are also thought to 
serve as storage of PUFAS and sources of lipid mediators, through the 
metabolism of PUFAs [3]. The importance of plasmalogens in health is best 
understood from the disease perspective, as a deficiency in the biosynthesis of 
plasmalogens is the cause of RCDP, a developmental disorder with defects in 
bone, brain, and eye development. In addition, other disorders, including 
Zellweger syndrome, Alzheimer’s disease, X-linked adrenoleukodystrophy have 
defects in plasmalogens which are thought to modulate the disease presentation 
and progression [3]. As plasmalogens are highly enriched in the nervous tissue, 
and given that in most human disorders with defects in plasmalogens, 
neurodegeneration is a feature of the disease, it is important to understand the 
consequences of plasmalogen defects to nervous tissue. Our main aim was to 
determine the role and importance of plasmalogens in the myelination of the 
peripheral nervous system, through the assessment of the phenotypic 
presentation and sciatic nerve pathology of knockout mice with defects in the 
biosynthesis of plasmalogens. 
Previous work at the Nerve Regeneration group, has revealed that a 
deficiency in plasmalogens impairs the initial stages of myelination, through a 
dual process: (1) - defects in plasmalogens impair the process of radial sorting, 
leading to the accumulation of large calibre axons in bundles, which fail to be 
segregated for myelination; and (2) – defects in plasmalogens impair the 
myelination process, as sorted axons showed increased g-ratio, indicative of less 
myelin. Despite this initial defect, we observed a normal degree of myelination in 
sciatic nerves from adult knockout mice. This led us to raise two main questions: 
despite the normal amounts of myelin in nerves from adult knockout mice, is the 
organization of myelin and the myelinating Schwann cell normal? Does a 
plasmalogen deficiency affect myelin maintenance in aged mice? 
Using our approach, the phenotypic characterization of plasmalogen-
deficient mice revealed that plasmalogen-deficient mice acquired an age-
dependent neuropathy, as they developed ataxia and tremors. On average, the 
knockout mice reached a humane end point at 17 months of age, as the severity 
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of ataxia progressed from locomotion and gait impairments to hindlimb paralysis, 
and from tremors to a comatose-like state.  Histological and ultrastructural 
analyses of sciatic nerves from aged knockout mice revealed a severe 
demyelination and axonal loss. Demyelination was evident not only by the 
thinning of the myelin sheath but also by the presence of axons completely 
devoid of myelin. Probably in an endeavour to remyelinate, we observed that 
Schwann cells from knockout mice produced and extended processes to attempt 
to engulf demyelinated axons and initiate the remyelination process. 
Nevertheless, the endoneurium of sciatic nerves from plasmalogen-deficient mice 
is filled with these processes, and we observed that even non-myelinating 
Schwann cells (forming the Remak bundle) extended these processes, and what 
appears to be still normally myelinated axons, contain several processes around 
them. Combined, our results indicate that a plasmalogen deficiency impairs the 
Schwann cell ability to maintain myelin and to respond to demyelination (Figure 
26). The reason behind this is currently unknown, although given the role of 
plasmalogens as antioxidants and the increase in oxidative stress with age, it 
might be possible that the lack of plasmalogens renders myelin more prone or 
sensitive to oxidative damage leading to demyelination. Future work should 
include the measurement of oxidative stress markers, to determine if an 
accumulation of oxidative damage is behind the loss of myelin. Nevertheless, our 
results showed that before the onset of demyelination, sciatic nerves from 
knockout mice are dysmyelinated, i.e., despite having normal myelin thickness 
the organization of myelin is abnormal. We observed that plasmalogen-deficient 
myelin has a greater number of Schmidt-Lanterman incisures and a disruption of 
Schwann cell appositions. The abnormal cytoarchitecture of the mutant Schwann 
cells also caused some abnormalities in axons, as we observed a diffuse 
localization of Caspr, which is normally localized to the paranode. Combined, our 
results indicate that in the absence of plasmalogens, Schwann cells are able to 
produce normal amounts of myelin, but its structure and organization is 
abnormal. This defect may not only contribute to the reduced nerve conduction 
but also to decreased myelin stability, which may modulate the demyelination we 
observed in aged mice. 
 In order to attain a deeper understanding of how a plasmalogen deficiency 
causes impaired radial sorting and myelination, we set out to determine the 
cellular changes in terms of signalling pathways. For this we used lysates of 
Chapter V │ Discussion 
71 
 
sciatic nerves from 15 days old WT and knockout mice, which we probed by 
western blot for the expression of several key kinases. From our small screen 
analyses, we identified AKT as a kinase that is differentially phosphorylated in 
sciatic nerve lysates from knockout mice. Receptor-mediated activation of AKT is 
mediated by its translocation from the cytosol to the membrane, where it is 
phosphorylated at Ser473 and Thr308 [105]. Upon phosphorylation, active AKT 
shuttles back to the cytosol where it can phosphorylate a myriad of substrates 
[110]. The phosphorylation by AKT can be either inhibitory or activating 
depending on the target and the residue that it phosphorylates. From the myriad 
of AKT substrates we analysed two, namely c-RAF and GSK3, as they could have 
a role to play in the pathology observed in nerves from plasmalogen-deficient 
mice. GSK3β has a non-myelinating effect which prevents the passage of Schwann 
cells from immature to a pro-myelinating stage, thus mediating both axonal 
sorting and myelination itself [89]. During normal postnatal development, GSK3β 
needs to be phosphorylated by AKT at Ser9 in order to be inactivated and allow 
the differentiation and maturation of Schwann cell to myelin-producing glia.  
When c-RAF is phosphorylated by AKT at the highly conserved Ser259, it acquires 
an inactive state [111] becoming unable to perform its kinase activity and, this 
way, interfere with myelination [74]. In our analysis, combined with the reduced 
phosphorylation of AKT, we observed a reduced phosphorylation of GSK3 at Ser9 
and c-RAF at Ser259. As such, our results indicate that a deficiency in 
plasmalogens causes impaired AKT-mediated signalling, and that GSK3 and c-
RAF may play a role in the cellular changes that cause impaired radial sorting and 
myelination (Figure 26). 
 In order to understand how a plasmalogen deficiency could affect AKT 
activation and its signalling pathway, we investigated AKT activation in detail. We 
hypothesised that a defect in AKT activation could be either, receptor/ligand-
mediated or receptor/ligand-independent. In the former hypothesis, a 
plasmalogen deficiency could affect receptor localization, its interaction with a 
given ligand or its activation (e.g. by dimerization), which would not initiate a 
signalling cascade failing to phosphorylate AKT. This hypothesis predicted that a 
plasmalogen deficiency would cause impairments in receptor/ligand interactions 
and functions, in a way that is specific for each cell type and tissue. In Schwann 
cells impaired NRG1 signalling via ErbB2/3 would cause reduced AKT activation, 
but in neurons the receptor affected would be different, and the same would be 
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true for all the tissues where a plasmalogen deficiency causes pathology. This 
would imply that in every tissue/cell with a plasmalogen deficiency (ranging from 
eye, testis, bone, neurons, to harderian gland and adipose tissue) a different 
receptor would be affected. Therefore we wondered if a plasmalogen deficiency 
would cause a receptor/ligand-independent defect in AKT activation. In this 
scenario, we hypothesized that a plasmalogen deficiency would impair AKT 
phosphorylation down-stream of receptor activation, in a cell type and tissue 
independent manner, and could explain the myriad of cellular defects and tissue 
pathology in RCDP patients and knockout mice. 
Our results showed that the impaired AKT activation is cell-independent, as 
MEFs from Gnpat knockout mice also had reduced levels of phosphorylated AKT. 
In addition, we showed that upon serum stimulation MEFs from Gnpat knockout 
mice were unable to activate the AKT-mediated signalling cascade, but they were 
able to induce ERK1/2 activation. These results suggested that our hypothesis of 
a receptor/ligand-independent defect in AKT activation would be behind a 
plasmalogen deficiency. For AKT to be phosphorylated and activated, 
unphosphorylated AKT needs to associate with the plasma membrane. As such, 
there is a shuttle of AKT from the cytosol to the membrane and back to the 
cytosol to phosphorylate its target proteins. We hypothesized that a defect in 
plasmalogens could impair the association of AKT to the membrane, and 
therefore block AKT phosphorylation. Using differential permeabilization and 
protein extraction, we found extremely reduced levels of AKT phosphorylation in 
the membrane fraction of MEFs from Gnpat knockout mice, suggesting either a 
defect in the kinases that phosphorylate AKT or in its ability to become 
membrane associated with subsequent phosphorylation. Our preliminary results 
(data not shown) revealed that the levels of PDK1 and PTEN are normal in sciatic 
nerve lysates from knockout mice, suggesting that a deficiency of plasmalogens 
at the plasma membrane impairs AKT activation and its signalling pathway. 
Recently, it has been shown that feeding an alkyl-glycerol to Pex7 knockout 
mice is able to rescue the defect in biosynthesis of plasmalogens, as alkyl-
glycerol serves as an alternative precursor [112]. In several tissues (e.g. liver, 
kidney, eye, testis and heart) the alkyl-glycerol treatment normalizes the levels of 
plasmalogens and is able to prevent or halt the pathological alterations. 
Nevertheless, the treatment was inefficient in rescuing the levels of plasmalogens 
in nervous tissue. In our work, the unravelling of the mechanism behind a 
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plasmalogens deficiency in the peripheral nervous tissue, allowed us to devise 
and test a therapeutic intervention aimed, not at restoring plasmalogen levels but 
at rescuing the impaired signalling pathway. 
 As discussed above, GSK3β is thought to play an important role during 
radial sorting and myelination. Given our results, we hypothesized that chemical 
or pharmacological inhibition of GSK3β would be able to circumvent the impaired 
inhibitory phosphorylation at Ser9, and allow the differentiation of Schwann cells. 
We have investigated if treatment with lithium chloride (LiCl) would have 
beneficial effects, as lithium is widely used to treat neurological diseases such as 
bipolar conditions and is a well described GSK3β inhibitor [89], [109], [106], 
[107]. 
 As the addition of LiCl, to in vitro myelinating co-cultures of DRG neurons 
and Schwann cells from knockout mice, resulted in a rescue of myelination, we 
initiated in vivo studies at two different developmental stages. To determine that 
the LiCl treatment would have a positive outcome in the AKT-mediated signalling 
pathway we determined the levels of phosphorylated AKT in sciatic nerves from 
15 days old WT and knockout mice. Our results showed that the administration of 
LiCl for 8 days was able to increase the levels of phosphorylated AKT. LiCl has a 
complex and wide range of action [108], and our results confirm that in addition 
to the expected direct inhibitory effect on the activity of GSK3β, LiCl is also able 
to increase the levels of phosphorylated AKT (possibly by inhibiting the 
phosphatase PP2a) [109], which may result in a further inhibitory action on GSK3β 
by AKT-mediated phosphorylation at Ser9. To determine if LiCl administration 
would be able to rescue the defects in axonal sorting and myelination, we 
investigated if treatment with LiCl would be therapeutic during the active period 
of radial sorting and initial stages of myelination [89]. Western blot analysis of 
muscle lysates from 6 days old WT and Gnpat knockout pups, revealed that LiCl 
administration was able to increase GSK3β phosphorylation at Ser 9 by 7-fold. 
The treatment with LiCl was also able to induce differentiation of mutant Schwann 
cells, as we observed a decrease in the levels of Sox2 with a concomitant increase 
in the levels on Oct6. Sox2 is a negative myelination regulator and is 
overexpressed in nerve injury and in other scenarios in which the myelination 
process is impaired [65]. Being characteristic of the immature stage of the SC, its 
decrease in the LiCl treated condition leads to conclusion that the treatment 
might be effective. Oct6 is a positive myelination marker and acts in union with 
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Sox10 to activate Krox20 which is a pro-myelination transcription factor [113]. 
The increased levels of Oct6 together with the decreased levels of Sox2 combined 
with the ultrastructural analysis, showed an improvement in Schwann cell 
differentiation and maturation with increase in the myelination status of sciatic 
nerves from LiCl-treated Gnpat KO mice. Quantitative analyses of axonal density 
in bundles and sorted axons with pro-myelinating Schwann cells revealed that the 
treatment with LiCl was able to rescue the defect in radial sorting present in 
knockout mice. 
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Figure 26. Summarized model representing the pathology and mechanisms inherent to 
plasmalogen deficiency. In WT condition (upper panel; normal) there is a normal myelination process 
with an initial functional radial sorting accompanied by a normal AKT-mediated signalling pathway 
which leads to GSK3β inhibition. On the other hand, plasmalogen deficiency (lower panel; ether-
phospholipid deficiency) presents an impaired signalling pathway with a decrease in GSK3β inactivation 
and a concomitant impairment in radial sorting and initial stages of myelination. Lack of plasmalogens 
leads, in adult stages, to normal amount of myelin but abnormally formed and, with aging, to a 
demyelination phenotype accompanied by axon loss. 
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As final remarks, we can effectively assign important roles of plasmalogens 
in Schwann cells and to the myelination process. Although plasmalogens have 
been associated with regulation of membrane fluidity and with scavenging 
reactive oxygen species, we showed that they may also play an important role as 
determinants or mediators of the transient association that some proteins 
establish with the plasma membrane. Our studies revealed that plasmalogens 
enable the membrane association of AKT with its subsequent activation. In the 
peripheral nervous system, a deficiency in plasmalogens impairs AKT-mediated 
signalling, causing defects in axonal sorting and myelination in a GSK3-mediated 
process. The plasmalogen deficiency causes initially a hypomyelination of the 
PNS, which develops into a status of dysmyelination with roughly normal amounts 
of abnormally formed myelin. The combination of abnormally structured myelin 
with increased oxidative stress in aged PNS, leads to a severe neuropathy with 
demyelination and axonal loss. 
The defects in nervous tissue caused by a plasmalogen deficiency may not 
be rescued by treatment with the current alkyl-glycerol therapy, but our 
determination of the mechanism behind the nerve pathology, allowed us to 
unravel a new strategy that is able to rescue the axonal sorting and myelination 
defects. Future work should determine if the treatment with lithium is able to 
rescue the impaired remyelination in aged mice, and if the combination with 
alkyl-glycerol treatment is able to yield a truly potent therapeutic intervention to 
rescue the defects caused by a deficiency in plasmalogens. 
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